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ABSTRACT 
Primary gastric lymphoma (PGL) is the commonest extranodal lymphoma 
throughout the world. Like other in cancers, pathogenesis of PGL is believed to be a 
multistep process. Helicobacter pylori (HP) and Epstein-Barr virus (EBV) infections 
are suspected etiologic factors. Genetic abnormalities of p53 and bcl-2 genes are also 
thought to contribute in the tumor development. The distribution of the p53 mutation 
provides a useful molecular fingerprinting for identifying the carcinogenic agent 
involved. In this study, 46 PGL, including 14 low grade MALT lymphomas (LM), 15 
high grade MALT lymphomas (HM) and 17 diffuse large cell lymphomas without LM 
components (DLCL), were examined. Screening for EBV and HP was performed in all 
cases. Immunohistochemistry for expression of p53, bcl-2 and EBV LMP-1 were 
performed. All cases were screened for p53 gene mutations in exon 5-8 by single 
strand conformation polymorphism (SSCP). The mutations were confirmed by 
sequencing. In addition, 25 cases were examined for loss of heterozygosity (LOH) of 
peri-p53 chromosomal regions 17pl2-13.1. 
EBV was detected in 10 DLCL (60%) and none o f t h e MALT lymphomas 
(p<0.01). HP was found in all cases o fLM and HM (100%) as well as 6 DLCL (35%) 
(p<0.01). Expression ofp53 was detected in all EBV+ DLCL (100%), 86% of EBV-
DLCL, 73.3% of HM and 7% of LM. Expression of bcl-2 was detected in all LM 
(100%), 33% of HM, 57% of EBV- DLCL and 22% EBV+ DLCL. LMP-1 was 
detected in 30% of the EBV+ DLCL. An inverse relationship between p53 and bcl-2 
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was identified in 93% of LM, 78% of EBV+ DLCL. Mutations of p53 gene were 
detected in 24 cases, including 80% EBV+ DLCL, 14% EBV- DLCL, 60% HM and 
43% LM. Mutations ofexon 7 were found in 88% ofEBV+ lymphomas and only 19% 
ofEBV- lymphomas (p<0.01). Mutations of intron 8 were found only in EBV+ DLCL 
whilst mutations ofexon 6, introns 6 and 7 were seen only in LM and HM. Recurrent 
mutations of codon 242 were noted in 50% of EBV+ DLCL. Recurrent (2 cases) 
mutations of intronic nucleotides 14115 and 13450, were seen in EBV+ DLCL and 
MALT lymphomas respectively. LOH abnormalities were seen in 4/5 (80%) ofEBV+ 
DLCL (including the 2 cases negative for p53 mutations) and 20% of EBV-
lymphomas, including 3/7 (43%) HM, 1/8 (13%) of LM and 0/5 (0%) EBV- DLCL 
(p<0.01). 
ki conclusion, the distribution of p53 mutation in HM and LM show marked 
similarity, supporting the hypothesis that HM probably arises from progression ofLM. 
The distribution of p53 mutation is significantly different between DLCL, especially 
EBV+ DLCL, and the MALT lymphomas, suggesting that a different carcinogen may 
be involved. Higher rates of p53 mutation and LOH abnormalities are seen in EBV+ 
than EBV- PGL. This suggests that p53 gene abnormalities are more important in the 
development ofEBV+ PGL. EBV+ DLCL shows 100% correlation of p53 expression 
with p53 genetic abnormalities (mutation and / or LOH). Lti contrast, the correlation in 
the EBV- PGL is much weaker. HP is associated with MALT lymphomas but not 














HP 在所有的 LM 和 HM (100%)及6例 DLCL (35%) ( P < 0 . 0 1 )爲陽性� p 5 3 蛋 
白表達在所有 EBV+ DLCL (100%) ’ 86% EBV- DLCL，73.3% HM 及7% LM 中爲陽 
性 ° bcl-2 蛋白表達在所有 LM (100%)，33%HM, 57% EBV- DLCL 及22% EBV+ DLCL 
中爲陽性。LMM在30% EBV+ DLCL中可檢測到。在93%的LM及78%的EBV+ 
DLCL顯示了 p«與bcl-2的負相關。？53基因突變在24例中檢測到，其中包 







4/5 (80%)的EBV+ DLCL (包括無p 5 3突變2例），2 0 %的E B V -淋巴 
瘤：包括3/7 (43%) HM, 1/8 (13%) LM 和 0/5 (0%) EBV-DLCL 顯示了 LOH 異 
常(?<0.01) ° 
總結，HM及LM 口53突變的分佈呈現了明顯的相似性，支持假說：HM可 
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1.1 Gastric Lymphoma 
1.1.1 Background 
Primary gastric lymphoma is the commonest extranodal lymphoma. In westem 
populations, up to one-fourth of all primary extranodal lymphomas originate within the 
stomach. Primary gastric lymphoma comprises up to 5% of all stomach tumors and 
accounts for roughly 60% of all primary gastrointestinal lymphomas (Rustgi, 1995). In 
Hong Kong, the percentage is even higher, with PGL comprising 39% of all extranodal 
lymphomas in a large series (Ho et al.’ 1984). 
By definition, primary gastric lymphoma exhibits no evidence of liver, spleen or 
bone marrow involvement at the time of diagnosis. Regional lymph node involvement 
may be present (Weingrad et aL, 1982). It is characteristically a disease of the sixteenth 
and seventeenth decades. The male to female ratio is 1.7:1 (Rustgi, 1995). 
Clinically, the most common complaint is boring and dull epigastric pain. Many 
patients also present with weight loss and anorexia, although this is less common. 
Outlet obstruction and associated nausea and vomiting are uncommon. On examination, 
an abdominal mass may be present in up to one-third of patients. Bleeding and 
perforation are less common (Weingrad et al, 1982). 
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L1.2 Mucosa-AssociatedLymphoid Tissue 
Bienenstock first used the term “MALT to describe the organized lymphoid 
tissue (B-cell nodules with follicular formation, with or without germinal centers) 
associated with the mucosa of the intestine and bronchial tissue, which he called gut-
associated lymphoid tissue (GALT) and bronchus-associated lymphoid tissue (BALT), 
respectively. He and others (Bienenstock et al., 1973a and 1973b; McDermott and 
Bienenstock, 1979) showed the relationship between MALT, luminal antigen-processing 
and B-cell mucosal immunity. The prototype of MALT is Peyer's patches of the small 
intestine. They comprise dome-shaped bulging subepithelial nodules of organized 
lymphoid tissue. Within these nodules, there is usually a follicle, often secondary, with a 
germinal center surrounded by a mantle zone, presumably reacting to antigen. However, 
much less noticeably in the normal state, surrounding the mantle zone there is a further 
layer of B-cells. These B-superficially resemble the small-cleaved cells of germinal 
centers in appearance and are thus called centrocyte-like cells. They are neither true 
follicular center cells (lacking CD10 antigen) nor mantle cells (lacking CD5). They 
selectively infiltrate the dome epithelium. Immunophenotypically they are identical to 
the splenic marginal zone lymphocytes. Within the surface epithelium, there are 
scattered intraepithelial T-cells which are generally of cytotoxic phenotype (CD8+). 
Within the laminal propria, there are helper T-cells (CD4+). There are also IgA-




However, MALT is not a normal component of the gastric mucosa. Recent 
studies suggested that it is an acquired phenomenon related to Helicobacter pylori (HP) 
infection. The bacilli stimulate a sustained antigenic response mediated through growth 
factors from mucosal CD4+ T- helper cells (D'Elios et al., 1997). HP infection of the 
gastric mucosa is classically associated with proliferation oflymphoplasmacytic cells in 
the lamina propria, formation of lymphoid follicles and intraepithelial lymphocytes 
(Figure I.1.). 
L1.3 Classification of Primary Gastric Lymphomas 
Hodgkin,s disease is exceedingly rare in the stomach, nearly all cases are non-
Hodgkin's lymphomas (NHLs). Vast majority, 97% in our hospital, of gastric 
lymphomas are o f B cell lineage and only occasionally o f T cell types. Thirty percent of 
gastric lymphomas were low grade and 70% were high grade (Chan et aL, 1998). 
1.1.3.1 Mucosa- associated Lymphoid Tissue Type Lymphomas 
m 1982, Isaacson & Wright introduced the concept of MALT lymphomas to 
explain and unify the special features of the commonest type of low grade gastric 
lymphoma. The concept is based on the observations that unlike nodal lymphomas, 
some lymphomas remain localized in the gastrointestinal tract for long period before 
disseminating to other organs. The tumor morphology recapitulates that of naturally 
occurring mucosa associated lymphoid tissue, exemplified by Peyer's patches. 
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The MALT lymphocytes have been postulated to have special "homing" 
properties. After leaving the mucosa via efferent lymphatics, they enter the peripheral 
circulation and then "home" back to the mucosa (Isaacson and Spencer, 1987). An 
integrin, a4pV, and L-selectin were later identified as mucosal homing receptors. These 
receptors mediate lymphocyte migration to the intestinal mucosa by binding to a 
vascular recognition molecule selectively expressed on mucosal endothelium Mad-, 
CAM-1 (Drillenburg et al, 1997). 
MALT type lymphoma is the most common type of low grade gastric 
lymphomas. Histologic features include proliferation of small-cleaved lymphoid cells 
with pale cytoplasm, the so-called centrocyte-like cells (CLC) (Figure I.2A). These 
cells may, sometimes markedly, show differentiation towards plasma cells (Figure 
I.2C). There is often a subepithelial zone of plasma cell proliferation. The CLC infiltrate 
and destroy glandular epithelium resulting in the characteristic lymphoepithelial lesions 
(LEL) (Figure I.2B&D). Occasional single or small clusters of blastic cells may be 
seen amongst the CLC. There are often abundant reactive lymphoid follicles in the 
background. The follicles may be colonized by CLC. Lnmunophenotypically, CLC 
express CD20 but lack CD23, CD5 and CD10. 
The monoclonality of CLC can be demonstrated in most cases. However, there 
remains a gray area where cases reported to be histologically diagnostic of MALT 
lymphoma but immunoglobulin gene studies found to be polyclonal (Hussell et al, 
1993). The reverse has also been observed, cases diagnosed as benign HP associated 
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gastritis were found to be monoclonal (Wotherspoon et al., 1991，Nakamura et al., 
1998). 
Low grade MALT lymphomas tend to remain localized until late in the course of 
the disease and hence often responds favorably to therapy. The overall prognosis of 
MALT lymphomas is considerably better than that of nodal tumors of similar 
histological grade (Isaacson and Spencer, 1987). As eradication o f H P may be curative 
of the low grade MALT lymphomas, antibiotic treatment has become the treatment of 
choice for this tumor in many centers (Zucca et al, 1994; Cammarota et al., 1995; Walt, 
1996; Copper et al., 1996), resulting in many fewer surgical resections. 
1.1.3.2 High Grade Primary Gastric Lymphomas 
Li 1994, Isaacson et al further expanded their MALT concept to include high 
grade gastric lymphomas. High grade MALT type gastric lymphomas can be either with 
low grade component or without low grade component (Isaacson, 1994). 
L1.3.2.i High Grade MALT Type Lymphomas 
Li high grade gastric lymphoma with low grade component (HM), the high grade 
component is composed of blastic cells and foci of low grade MALT lymphomas are 
identifiable (Figure I.3). The infiltrate of large neoplastic cells is more destructive, 
causing marked loss of glands. The large cells occur in diffuse sheets and clusters. The 
coexistence and intimate relationship of low grade MALT and high grade gastric 
lymphoma suggest that these high grade lymphomas arise through blastic transformation 
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of the low grade component. The high grade and low grade components were also 
shown to share the same light chain restriction (Chan et al, 1990). 
LL3.2.ii B-lineage Diffuse Large Cell Lymphomas 
Isaacson et al also included all remaining large B cell gastric lymphoma into the 
group "high grade MALT lymphoma" without low grade component (or past history of 
low grade MALT lymphoma), hereafter abbreviated to DLCL ^^igure I.4A). This 
group virtually includes all high grade B cell lymphomas other than Burkitt's 
lymphomas, arising in the stomach. The evidence for this claim is far from conclusive. 
Whereas studies on mucosal receptors have confirmed that most HM share with LM, the 
expression ofthese receptors, the high grade lymphomas with no low grade components 
were mostly negative (Drillenburg et al., 1997). In 2 studies from Hong Kong, it was 
shown that a significant number ofDLCL harbored the EBV and were negative for HP, 
whereas the reverse was true for the LM and HM lymphomas (Hui et al, 1994; Chan et 
al., 1995), clearly an inverse relationship. Li another study, the expression of three 
adhesion molecules, VCAM-1, ICM-1 and ELAM-1, were investigated in the 
microvasculature ofPGL. PGLs were classified into low grade MALT lymphomas and 
high grade lymphomas with or without a low-grade component. The proportion of 
venues positive for ELAM-1 or VCAM-1 was significantly higher in the high grade 
lymphomas without a low grade component than in the other two types (Sato et al., 
1996). Whereas trisomy 3 has been found in 60% ofLM (Wotherspoon et al, 1995), the 
CGH and FISH study have shown a high frequency of trisomy 12 and a lack of trisomy 
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3 in these DLCLs (Chan et al., 1998, Barth et al, 1998). All these studies strongly 
suggested that Isaacson's scheme is an oversimplification. High grade B cell lymphomas 
are not all ofMALT origin. 
1.1.3.3 Other Gastric Lymphomas 
A variety of other non-Hodgkin's lymphomas are occasionally found in the 
stomach. The most common is Burkitt's lymphoma, followed by follicular lymphoma 
and mantle cell lymphoma. Rare cases of anaplastic Ki-1 lymphoma and T cell 




L 2 Helicobater Pylori 
Previously known as Campylobacter Pylori, Helicobacter pylori (HP) is a gram-
negative bacillus discovered by Warren and Marshall in 1983. 
The strong association between HP and both peptic ulcer and gastric carcinoma 
are well known. Li Hong Kong, HP infection of gastric mucosa is present in 57.3% of 
patients with benign gastric ulcers (Chan et aL, 1991) and tissues from 76.6% cases of 
gastric adenocarcinoma show colonization of HP (Chan et al., 1994b). HP secretes 
urease, which generates the ammonia that provides the alkaline micro-environment in 
which the bacteria live. The protease of HP then breaks down the protective mucus 
glycoproteins of the gastric mucosa, exposing the underlying epithelial cells to acid / 
peptic ulceration. Epidemiologic studies have identified an association between HP and 
gastric carcinoma. HP is now classified as a grade I carcinogen by the World Health 
Organization (LVRC, WHO, 1994). Whilst the association between ulcers and 
carcinomas has been known long before the advent ofHP, little is understood about how 
HP may be involved in carcinogenesis. 
Only recently has it become apparent that there is an even stronger association 
between HP and low grade PGL. HP can be identified in over 90% of low grade PGL 
(Wotherspoon et al, 1991). Eradication o fHP has resulted in clinical and histological 
remission of low-grade MALT lymphomas (Wotherspoon et al., 1994; Walt, 1996). It 
seems that HP plays a significant role in MALT lymphomas development. 
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1.3 Epstein-Barr Virus (EBV) 
L3.1 Epidemiology 
EBV infects 90 percent ofthe world's population. Most individuals are infected 
in their childhood or young adulthood. The virus remains latent for life in a small 
proportion of lymphocytes. EBV is transmitted horizontally in humans mainly through 
saliva, and iatrogenically through blood transfusion and organ transplantation. Most 
human EBV infection starts in the stratified squamous epithelium oforal cavity (Isom et 
aL, 1996) and the epithelial cells in the parotid ducts, where cells are permissive for 
vims replication. However, human peripheral blood B-lymphocytes are the main target 
for EBV infection, with about 1 in 10^ to 10^ infected by EBV. 
L3.2 Virus and Genome Structure 
The Epstein-Barr virus is a member of the human herpesvirus family, which also 
belongs to the subfamily of Gammaherpesvirinae and the genus Lymphocryptovirus. It 
has a toroid-shaped protein core wrapped with a DNA, a nucleocapsid with 162 
capsomeres, a protein tegument between the nucleocapsid and the envelope and an outer 
envelope with external glycoprotein spikes. (Kieff, 1996). EBV is a large-enveloped 
icosahedral DNA virus, approximately 150nm in diameter (Isom et al., 1996). Its 
nucleocapsid encloses a linear double-stranded DNA. The EBV genome contains 172 
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kbp, mainly composed of 60 mole percent guanine and cytosine. The genome can be 
divided into three main parts include ( i ) the main genes encoding EBV proteins; ( i i ) 
tandemly reiterated 0.5 kbp terminal direct repeats (TR); and ( i i i ) tandemly reiterated 3 
kbp internal direct repeats (Hl) which divide the genome into short and long, largely 
unique sequence domains (US and UL, respectively). 
Infected B-lymphocytes express high levels of CD21, a cell surface glycoprotein 
and a member of the immunoglobulin gene super-family. This CD21 serves as the 
receptor for EBV and binds to the gp350/220 antigen on the virus's outer envelope. 
Apart from EBV recognition, CD21 promotes EBV uptake and the fusion between EBV 
envelope and membrane vesicles. The EBV-containing vesicles are then transported by 
the cytoskeleton to the nucleus. Within 12-16 hours of infection, the EBV genome 
circularizes in the nucleus. Depending on the cell-specific transcriptional factors, the 
infected cells enter the latent or lytic phases. The B-lymphocytes predominantly enter 
the latent phase, while the epithelial cells are tend to undergo lytic infection (Kieff, 
1996). Even though T cells normally lack CD21, they may express CD21 at certain 
stages of differentiation (Fischer et al., 1991). This may account for the presence of 
EBV in many types o fT cell lymphomas. 
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L3.3 Latent Infection 
Lti latent infection, EBV expresses at least 11 genes. Those genes are: EBNA 1， 
2, 3A, 3B and LP (encoding 6 different nuclear proteins); EBER 1 and 2 (encoding 2 
small non-polyadenylated RNAs); LMP 1, 2A, 2B (encoding 3 different integral 
membrane proteins). The main function of these viral proteins is to propagate the vims 
in the infected cells. EBNA 2 and LP appear first at 24-32 hours post-infection. By 32 
hours, EBNA 1, 3A, 3B, 3C, and LMP 1, 2A and 2B are also expressed. EBERs 
expressions are the latest, occurring at 56 hours post-infection (Kieff, 1996). Three 
distinct forms ofEBV latency have been identified, termed latency I, II and III, based on 
the phenotype of the target cell, expression of the key viral genes and the choice of 
promoters for the expression ofthe EBNA genes. Latency I was first reported in EBV-
positive Burkitt's Lymphoma (BL) cells, expressing EBNA 1, EBER 1 and 2. Latency 
II is found in BL cells and nasopharyngeal carcinoma (NPC) cells, expressing EBNA 1, 
EBER 1 and 2, and LMP 1 and 2. Latency III is the classical model of latency, which is 
observed in BL cells and the lymphoblastoid cell lines. Eleven genes are expressed in 
this type: EBNA 1, 2, 2A, 3B, 3C & LP, EBER 1 and 2, LMP 1, 2A & 2B. The cells of 
all forms of latency can be activated to enter the lytic cycle. This process involves the 
expression of two early lytic transcripts, BZLF 1 and BRLF1 (Rickinson et al, 1996). 
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L3.4 Latent Membrane Protein-l (LMP-1) 
LMP-1 is one of the proteins expressed by the EBV in the latent stage of 
infection. It is a 62 KDa integral membrane protein with 386 amino acids which 
consists of three major segments: ( i ) a cytoplasmic 24-amino acid amino-terminus 
intracellular region; ( ii ) a 162-amino acid transmembrane region divided into six 20-
amino acid, alpha-helical segments and linked by five short reverse tums; and ( iii ) a 
cytoplasmic 200-amino acid carboxy-terminal region (Fennewald et al, 1984). LMP-1 
protein is transcribed and translated from the BNLF-1 gene of EBV. BNLF-1, also 
called the LMP-1 gene, is located at the left-hand side of the oriP of the EBV episome 
and has three exons and two introns. 
LMP-1 can induce cell surface expression ofCD23, CD39, CD40, CD44, Class 
II major histocompatibility complex (MHC) and cell adhesion molecules (LFA-1, LFA-
3 and ICAM-1) in cultured cell lines. LMP-1 also activated NF-kappa B transcription 
factor, which leads to various cell signaling (Hammarskjold and Simurda, 1992; Laherty 
et al, 1992). LMP-1 was shown to have transforming properties in rodent fibroblast 
(Wang et al, 1985) and able to induce tumors in nude mice (Li et al., 1996). LMP-1 can 
transform B cells by blocking apoptosis through upregulation of bcl-2 (Henderson et al., 
1991) and by blocking the p53-mediated apoptosis via the A20 gene (Fries et al., 1996). 
The deletion of all the carboxy-terminus, except the first 44 amino acids, result in the 
failure of B-cell transformation (Kate et al, 1995). Other studies also found that the 
carboxy-terminus of LMP-1 but not the amino-terminus was needed for B cell activation 
(kumi et aL, 1994; Peng-Pilon et al., 1995). 
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L3.5EBV'Encoded, SmallNon-PolydenylatedRNAs (EBERs) 
EBERs are the most abundant EBV RNAs in the latently infected cells (10^ 
EBER 1 per cell and 10^ EBER 2 per cell) (Isom et al., 1996). The EBER 1 and 2 
localize in the cell nucleus, where they complex with the cellular La protein and nuclear 
EAP protein (Howe and Steitz, 1986). The exact role of the EBERs in EBV infection is 
not clear. However, as their detection by the method of in-situ hybridization is relatively 
uncomplicated and rapid, they are now used for EBV screening in tissue samples in 
research and service laboratories. 
1.3.6 Disease Associated with EBV 
The association of EBV with the human host is usually nonpathogenic. Li 
developing countries, primary infection nearly always occurs without any symptoms in 
the childhood. Li most cases, EBV infection remains a silent event, with seroconversion 
acquired by adulthood. The diseases will only be evident in the rare individuals and 
immunocompromised patients. The most common EBV-associated diseases can be 
classified into benign lymphoproliferative disease (LPD), malignant tumors (malignant 
lymphomas in immunocompetent immunocompromised patients as well as 
lymphoepithelioma-like undifferentiated carcinomas). 
Benign LPD includes infectious mononucleosis (JM) in healthy individuals and 
LPD of immunocompromised hosts, such as HrV+ and post-transplant patients. While 
in malignant lymphomas, EBV is associated with both Hodgkin's Disease and NHLs. 
Burkitt's lymphoma (BL) was the first disease found to be EBV-related. It is found that 
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EBV associated extranodal NHL is especially common in China, Taiwan and Hong 
Kong (Shih et al, 1991). Among all the NHLs, sinonasal T/NK lymphoma in the head 
and neck region is the most common, about 88%, NHL-EN associated with EBV. Other 
peripheral T cell lymphomas (PTL) in China are also frequently associated with EBV. 
Nasopharyngeal carcinoma QSfPC) has been conclusively proven to have a 100% 
association with EBV and have been studied extensively in the last 30 years. 
Lymphoepithelial-like carcinomas (LELCs) of the lung, stomach and salivary glands 
have all been shown to be associated with EBV (Wong et al, 1995; Ohfuji et al,, 1996; 
Sheen^r al, 1997). 
L3.7EBVandPGL 
DLCL without low-grade component comprised 18% of the gastric NHLs in 
Hong Kong (Hui et al, 1994). They account for 60% of the gastric DLCLs in Hong 
Kong. Similarly, 11% of gastric NHLs and 6% of intestinal NHLs are found to be EBV 
positive in Korea (Lee et al., 1997). 
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L4 Genetic Alterations 
I.4.I Background 
Cancer is fundamenta l ly a genet ic disease, in which d a m a g e d cel lular D N A leads 
to disrupt ion of the nomia l mechan i sms that control cel lular prol i fera t ion. It is bel ieved 
to evolve through clonal expans ion and accumula t ion of mul t ip le genet ic aberra t ions in 
cells. These genetic al terat ions include the act ivat ion of oncogenes and the inactivation 
of tiimor suppressor genes. (Levine, 1992; Volgelstein and Kinzler , 1992). Moreover , 
gcncs related to DNA repair, apoptosis and te lomerase activity are also found to be 
frequent targets o f a l t e r a t i ons dur ing the deve lopment of cancer. 
Oncogenes are considered as dominant , t r ans forming genes with activation or 
"gain of func t ion" due to al terations in only a single allele of the gene can cause cell 
t ransformat ion. Activat ion of oncogenes can occur through a variety of mechan i sms 
such as mutat ion, amplif icat ion, translocation aiid delet ions. T u m o r suppressor gcncs, 
similar to oncogciics. arc involved in thc regulation of cclliilar growth and 
ditTcrcnlialioii. Thcy are also termed rccessivc gciics bccausc it is only when both 
alleles of the gcnc arc inaclivalcd or "loss of funct ion", thc normal constrainl lo ccll 
proliferation is rcn io \cd , leading to ccll immortal izat ion. Tumor suppressor gciics 
ciuxxie proteins that inhibit ccll division. Their expression is iipregiilalcd in response to 
signals of DNA danuigc. Muialion may cause lhcsc tiimor suppressor protcins to bc 
inaclivalcd. Mutat ions can txciir in several clitTcrcnt forms, including niisscnse. 
tVanicshit^ and iuinscnsc nuilalions. Splicing nuilalions occur in lhc non-coding introns 
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and can affect the regulation of mRNA (Takahashi et al., 1990，Kikukawa et al., 1998). 
All of these DNA sequence changes will alter the function of the resulting protein, 
leading to increased risk of tumor development. Sequence changes also can represent 
"silent" mutation or polymorphisms, which alter the sequence of the gene but not the 
amino acid. 
L4.2 Tumor Suppressor Genes (TSGs) 
Tumor suppressor genes are of particular interest in cancer genetics as they are 
the genes most commonly associated with hereditary predisposition to cancer. It is 
proposed that genetic alteration of the TSGs in one allele may play a critical role in the 
initiation stage. Further alteration of the other allele acts as the determinant in the 
transition from promotion to progression stage. Table 1.1. lists some existing TSGs 
involved in the pathogenesis of a wide variety human cancers that have been widely 
investigated (Perkins and Stem, 1997). 
1.4.2.1 Origin and Structure of p53 Gene and Protein 
Among all tumor suppressor genes, p53 is one of the most studied. Mutations of 
this gene is involved in the development of up to 50-60% of all human cancers 
(Greenblatt et al., 1994; Hollstein et al., 1996). 
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The p53 protein was discovered independently by Linzer & Levine and Lane & 
Crawford. The p53 gene was originally thought to be an oncogene as its protein bound 
to the large transforming antigen of the SV40 DNA vims (SV40 T-antigen) (Linzer & 
Levine, 1979; Lane & Crawford, 1979) as well as the E l B oncoprotein of adenovirus 
(Samow et al., 1982). The binding of p53 protein to these two different oncogenic viral 
tumor proteins suggested that p53 was crucial to tumorigenesis. Soon thereafter, it was 
found that the oncogenic form of p53 is actually a mutant, while the wild-type protein is 
a tumor suppressor. Although the p53 gene was isolated and characterized in 1982 
(Matlashewski et aL, 1984; Lamb & Crawford, 1986)，it was not proved to be a tumor 
suppressor gene until 1988. Vogelstein first observed that an extremely high percentage 
(about 80%) of colon cancers showing LOH on chromosome 17p as well as mutations in 
the p53 gene (Vogelstein et al., 1988; Baker et al., 1989). Many mutant forms of p53 not 
only lose their tumor suppressing activity, but also acquire oncogenic activity. Many of 
the original experiments, which suggested that p53 was a dominant oncogene, actually 
used mutant forms ofp53. 
The p53 gene spans 20 kilobases (kb) of genomic DNA, It is located at 
chromosome 17pl3.1, approximately 15-20 centimorgans from the telomere. It consists 
of 11 exons, including a 5，non-coding exon (exon 1) located significantly upstream that 
is 8-10 kb away from the exons 2-11 and contained 213 base pairs in size (Lamb & 
Crawford, 1986). The gene contains five evolutionarily conserved domains which have 
been shown to harbor the vast majority of p53 mutations in many studies (Gaidano et al., 
1991; Ichikawa et al, 1992; Bhatia et al., 1992). These conserved domains are found to 
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lie within exons 5, 7 and 8, include domain I in codons 13-19; domain II in codons 117-
142; domain EI in codons 171-181; domain W in codon 234-258 and domain V in 
codon 270-286 (Soussi et al, 1990). The p53 gene also encodes a 393 amino acid 
nuclear phosphoprotein, with a molecular weight of 53 kilodalton (kd). The protein has 
three fimctional domains: (1) a region at the amino-terminus rich in acidic amino acids, 
containing the transcriptional activation region; (2) a highly conserved hydrophobic 
conformation region rich in proline residues, with sequence-specific DNA-binding 
activity; and (3) a region rich in basic amino acids at the carboxy-terminus (Pavletich et 
al, 1993; Wang et al” 1993). Li addition, the p53 protein can be functionally 
subdivided into 4 distinct and separable units: (1) a transactivation domain at residues 
1-43; (2) a DNA binding domain at residues 100-300; (3) an oligomerization domain at 
residues 320-360; and (4) a nuclear localization domain with non-specific DNA binding 
activity between residues 330-393 (Sahulian et al., 1993). The p53 protein is located in 
the nucleus, however, it is extremely unstable with short half-life in a range of 15-30 
minutes. So wild-type p53 protein is present at very low levels in normal cells. Li 
contrast, the p53 mutants have longer half-life, and therefore more stable than wild-
type. The accumulation of mutant p53 within cells makes it more readily detectable by 
immunohistochemical methods their wild-type counterparts. 
1.4.2.2 Functions of p53 Gene 
p53 has been named as the "guardian of the genome" by many researchers (Lane, 
1992). As wild-type p53 is a tumor suppressor, it can repress abnormal cell proliferation 
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and growth by transcription in case of any DNA damage. Li response to DNA damage, 
p53 protein binds to the specific DNA sequences, which regulate the transcription ofthe 
genes to control cell birth and cell death. Some genes that are regulated positively by 
p53 include p21, GADD45, MDM-2 and RB while the negatively regulated genes 
include c-jun, c-fos and p—actin. 
L4.2.2.i p53 as a DNA binding transcription factor 
Mrinsic to the function ofthe p53 protein is its ability to regulate transcription 
through sequence specific DNA binding, p53 proteins tetramerize (McCormick et al., 
1981), and the tetramers bind specifically to a p53 responsive element containing repeats 
of the consensus binding sequence. Binding of wild-type p53 to its cognate response 
element regulates transcription through nearby promoters, and can cause both the up or 
down regulation of transcription. Li addition, p53 can modulate transcription through its 
interaction with the TATA binding protein (TBP) (Liu et al., 1993), transcription 
associated factors hTAFn32 and hTAFn70 (Thut et al., 1995) and the adeonvirus ElB 55 
kd oncoprotein (Lin et al., 1994). 
I.4.2.2.ii p53 and DNA Damage Response 
As the eukaryotic cell cycle consists of sequential rounds of chromosomal DNA 
synthesis (S) and segregation by mitosis (M), separated by the two intervals of G1 and 
G2, respectively. Transition between the Gl/S and G2M boundaries of the cell cycle is 
under the biochemical control of the cyclin family of proteins. Cyclins function by 
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binding to and activating the kinase activity of cyclin dependent kinases (Cdks). The 
active heterodimer of a cyclin and its cognate Cdk then phosphorylates other cyclin 
expression. Cdk activation is crucial to the control of cellular proliferation, and cyclin 
de-regulation may be an important step during cancer development. The biochemical 
machinery which regulates transition between phases of the cell cycle is collectively 
described as checkpoints, which ensure that the cell cycle remains in synchrony with 
both intracellular events and environmental cues (Hartwell and Weinert, 1989). Jn 
addition, there are DNA damage checkpoints at the Gl/S and G2/M boundaries, which 
ensures that damaged DNA is repaired prior to entry into S or M. Hence, another 
function of wild-type p53 is to help to maintain genetic stability by initiating a transient 
G1 cell cycle arrest that allow time for repair ofdamaged DNA before entry into S phase 
(Michalovitz et aL, 1990). Li response to DNA damage, increase of p53 leads to 
transcriptional up-regulation of the Cdk inhibitor p21. This p53 dependent increase in 
p21 levels leads to an inhibition of cyclin E-Cdk2 kinase activity. As cyclin E kinase 
activity is the rate-limiting step for the Gl/S transition, hence increase in p21 levels 
during DNA damage results in a Gl/S cell cycle arrest. On the other hand the p53-
induced gene, GADD45, a member of the GADD (growth arrest and DNA damage 
inducible) family of genes, may also be involved in the DNA damage response (Smith et 
al , 1994). As GADD45 binds PCNA (proliferating cell nuclear antigen) and stimulates 
excision repair, the transcriptional activation of genes by p53 may also arrest the cell 
cycle during DNA damage. 
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1.4.2.2. iii Induction of p53-dependent Apoptosis 
Apoptosis is a unique pathway of cell death and also describes as cell suicide. 
During apoptosis, cells shrink in volume, their cytoskeleton breaks down, chromosomes 
condense and finally nuclear DNA is cleaved into small fragments. Li fact, the apoptotic 
pathway may have evolved as a mechanism to protect organisms from cells, with 
sustained DNA damage and therefore, malignant potential, p53 acts as a "guardian of 
the genome" preventing proliferation of unwanted and possibly malignant cells in case 
of severe DNA damage (Lowe et al., 1993). Li hypoxic environment, such as within a 
tumor, normal p53 protein induces apoptosis. Loss of p53 function enables hypoxic 
tumor cells to escape this proliferation control (Levine, 1997). 
L 4.2.2.iv Induction of Cellular Differentiation 
Another function of p53 is the induction of cellular differentiation. Wild-type 
p53 induces B cells to differentiate (Prives and Manfredi., 1993) and activates the 
expression of the muscle creatine kinase gene, which is tumed on during muscle cell 
differentiation. 
1.4.2.3 Inactivation Mechanisms of p53 
Despite of the tumor suppressor function of wild-type p53, it may be down-
regulated by disruption of the p53-signaling pathway. Several mechanisms can 
inactivate p53 function at either the gene or the protein level: 
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L4.2.3.i Mutation of the p53 gene 
The frequent mutation of p53 in a wide spectrum ofhuman cancers suggests that 
p53 inactivation is a crucial and often obligatory step during tumorigenesis. According 
to the two-hit hypothesis of tumor suppressor gene proposed by Alfred Knudson in 1971, 
a point mutation in one copy of the normal gene is usually accompanied by the loss of 
the remaining allele (Knudson, 1971). Recent studies with analysis of more than 5,000 
human tumor samples, representing 43 different tumor types, revealed that 50-60% of all 
cancers have a mutated p53 gene (Greenblatt et al, 1994; Hollstein et al., 1996). Li 
addition, it is further revealed that 85% of these mutant alleles of p53 consist of 
missense mutations, usually involving a single amino acid substitution, within the DNA 
binding core domain (Hollstein et al., 1991; Harris, 1993; Greenblatt et al, 1994). 
Disruption of DNA binding prevents p53 from functioning as a transactivator and 
consequently inhibits its tumor suppressor activity. Although in Li-Fraumeni syndrome, 
only homozygous mutations result in abnormal p53 protein stabilization, a heterozygous 
p53 mutation can also act with dominant effect, only the abnormal protein from the 
mutated allele is stabilized. Some mutations may result in an abnormal protein gain of 
function (Bhatia et al, 1993). 
1.4.2.3. ii Molecular Fingerprinting 
There is a significant preference for particular p53 mutations in individual tumor 
types. For example, mutated p53 genes from colon tumors and non-aflatoxin associated 
hepatocellular carcinoma typically contain a G-C to A-T transition, while small cell lung 
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cancers and aflatoxin B1 associated hepatocellular carcinoma usually have a G-C to T-A 
substitution at codon 249 (Aguilar et al, 1993). The unique spectra of p53 mutations in 
different tumor types likely reflect the role that individual carcinogens play in tumor 
etiology and in inducing p53 mutation, so-called molecular fingerprinting. Thus, the 
presence of unique p53 mutation in human cancer makes it possible to identify the 
carcinogen involved in the development of different tumors (Hussain and Harris, 1998). 
L4.2.3.iii Specific Binding to DNA Tumor Virus Oncogenes 
Wild-type p53 tumor suppressor function can also be inhibited by several DNA 
tumor viruses. The latter encode oncoproteins that inactivate wild-type p53 protein 
(Levine, 1990) such as HPV E6 protein, SV40 large T-antigen, adenovirus ElB protein. 
It has been shown that E6 gene product ofhuman papilloma virus type 16 and 18, which 
are associated with cervical carcinoma, specifically binds wild-type p53 and targets p53 
for degradation (Scheffiier et al, 1990). Thus, elimination of p53 protein by papilloma 
virus is consistent with a loss of tumor suppressor function. 
I.4.2.3.iv Binding to MDM-2 Cellular Oncogene 
An oncoprotein, MDM-2, is the product of the murine double minute (MDM-2) 
gene. It is originally identified in a spontaneously arising tumorigenic murine Balb/c 
3T3 fibroblast cell line (3T3DM) by Donna George (Cahilly-Snyder et al., 1987). 
MDM-2 negatively regulates wild-type p53 mediated transcription by directly binding 
the p53 protein (Momand et al, 1992). It is indicated that p53 and MDM-2 are 
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regulated by a negative feedback loop. Li this mechanism, p53 stimulates MDM-2 
expression, while induction of MDM-2, by virtue of its ability to complex with p53, 
down-regulates wild-type p53 transactivation function. MDM-2 amplification has been 
found in approximately one-third of human sarcomas (Oliner et al, 1992) in which loss 
of wild-type p53 function is involved in those tumors with amplification of MDM-2 
(Prives and Manfredi, 1993). 
1.4.2.4 p53 Mutations and Protein Expression in NHLs 
Among the recent studies ofNHLs, p53 mutation was found in 7-45% (Ichikawa 
et al, 1992; Villuendas et al, 1993; Kocialkowski et al, 1995; Ichikawa et al, 1997; 
Martinez-Delgado et al, 1997; Park and Lee, 1998 and Chen et al., 1999). In MALT 
lymphomas, 18-33% had p53 mutation including both high grade and low grade MALT 
(Du et al., 1995; Peng et al, 1996; and Gaidano et al., 1997a). The percentage of 
mutation was higher (33%) in high grade MALT lymphoma (Du et al, 1995). Nakamura 
et al, (1996) also noted that p53 overexpression increased in high grade gastric 
lymphomas and associated significantly with poor prognosis. 
One effect of p53 mutations in the evolutionarily highly conserved exons is to 
stabilize the p53 protein. This results in a much higher level of intracellular mutant p53 
in the steady state. The immunohistochemical detection of p53 was initially thought to 
correspond to p53 gene mutation. However, later studies have failed to demonstrate p53 
mutations in cases with p53 expression (Fimegan et al, 1994; Villuendas et al, 1997). Jn 
2 4 
Introduction 




Bcl-2, B cell lymphoma-2 gene was first identified through its involvement in B 
cell lymphomas. It was discovered adjacent to the breakpoint of a chromosomal 
rearrangement commonly seen in follicular B cell lymphoma (Tsujimoto and Croce, 
1986). The rearrangement involves translocation of a portion of the long arm of 
chromosome 18 to the long arm of chromosome 14. This translocation causes bcl-2 
gene (located at chromosome 18q21) to be juxtaposed to the immunoglobulin heavy 
chain locus (at chromosome 14q32) without interruption of the coding region of bcl-2. 
The consequence of the translocation is high levels of bcl-2 protein resulting from both 
enhanced transcription and, possibly, more efficient RNA processing fNgan et al” 
1998). 
The bcl-2 gene encodes a 26 kd integral membrane protein that has been 
localized to mitochondria, endoplasmic reticulum and perinuclear membrane 
(Korsmeyer, 1992). The C-terminal 21 amino acids encode a stretch of hydrophobic 
amino acids that are required for insertion into membranes (Chen-Leavy and Cleary, 
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1990). It has been demonstrated that insertion into membrane is closely associated with 
the ability of bcl-2 to regulate apoptosis (Hockenberry et al., 1990). The bcl-2 gene is 
only one member of a family of apoptotic regulators, which also includes bax and bcl-x 
(Boise et al., 1993). It is now clear that bcl-2 exists as part of a high molecular weight 
complex generated through heterodimerization with bax (Oltvai et aL, 1993). The 
intracellular ratio of bcl-2 to bax determines the functional activity of bcl-2. If bax is in 
excess, bax homodimers dominate and cell death is accelerated; conversely, when bcl-2 
is in excess, bcl-2 / bax heterodimers are the prevalent species then cell death is 
repressed (Yin et al., 1994). 
Bcl-2 can be regarded as a member of the oncogenes involved in cell survival, 
by blocking programmed cell death, also called apoptosis. In contrast to most proto-
oncogenes of lymphoid neoplasia, bcl-2 has little or no ability to promote cell cycle 
progression or cell proliferation. As a result of the translocation t(14;18) (q32;q21), 
production of high levels of bcl-2 protein is observed in the majority of the follicular 
lymphomas and in about 20% of diffuse large B cell lymphomas (Pezzella et al, 1990; 
Jacobson et al., 1993). However, the mechanism ofbcl-2 protein is not restricted to B-
cell lymphomas bearing t(14;18) translocation. Indeed, immunohistochemical studies 
have shown that, beside follicular lymphomas, a broad spectrum of lymphoid 
malignancies including chronic lymphocytic leukemia, plasma cell dyscrasia as well as 
non-lymphoid tumors of lung, breast, prostate or liver origin, also express bcl-2 protein. 
In addition, bcl-2 protein is also detected in a number of normal lymphocytes, including 
B lymphocytes of the mantle zone and normal T cells (Hockenbery et al, 1991). 
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Expression of bcl-2 protein is found in majority of both low and high grade follicular B 
cell lymphoma (Gaulard et al, 1992). Whereas though there is high frequency of bcl-2 
expression in the majority of low grade MALT lymphomas, in high grade MALT 
lymphoma there is little bcl-2 expression (Villuendas et al, 1991). This might indicate 
that the normal cellular control mechanisms which suppress bcl-2 protein production in 
activated B-cells in germinal centers (Ashton-key et al, 1995), are operative in high 
grade MALT tumors. However, MALT lymphomas are derived from mucosal pool of 
lymphocytes and not from follicular centers. Furthermore, low grade MALT lymphomas 
only rarely harbor the t(14;18) rearrangement (Pan et al, 1989; Gaidano et al, 1997b). 
Immunohistochemical bcl-2 expression is not specific for t(14;18) rearrangement 
(Pezzalla et al, 1990). Expression of bcl-2 is detectable in benign mucosal plasma cells, 
mantle cells and T cells. As centrocyte-like B cells are not a normal component of the 
gastric mucosa, it is difficult to know whether bcl-2 expression is a normal phenotype. 
However, the closest benign equivalents are the subepithelial B cells of the palatine 
tonsils and splenic marginal zone B cells. These B cells express high levels of bcl-2 
(Dono et al, 1996). Listead of interpreting the high bcl-2 expression oflow grade MALT 
as abnormal, there may be a loss ofbcl-2 expression in high grade MALT lymphomas. 
1.4.3.2 Other Oncogenes 
Apart from bcl-2 gene, other oncogenes such as c-myc and bcl-6 have been 




Translocation involving the c-myc locus (region 8q24), with its activation, is 
frequently detected in Burkitt's or Burkitt-like lymphomas. Rearrangements of c-myc 
were said to be found in 50% of difftise large cell lymphomas or high grade MALT 
lymphomas in the gastrointestinal tract (van Krieken et al., 1990). 
L4.3.2.ii Bcl-6 
Chromosomal abnormality of the bcl-6 gene at 3q27 also represents a common 
genetic lesion in lymphomas. Bcl-6 gene encodes a 79 kd zinc-fmger protein which acts 
as a transcriptional regulator during cell proliferation and / or differentiation (Ye et al, 
1993). Approximately 40% of diffuse large cell lymphoma and 20% of AK)S-related 
cases has been detected with bcl-6 rearrangement (Lo Coco et aL, 1994; Gaidano et al, 
1997b). Bcl-6 gene rearrangement was not seen in low grade MALT lymphomas but 
may be found in 27.2% of high grade MALT lymphomas (Gaidano et al, 1997b). 
Expression of bcl-6 was found to be associated with better prognosis in high grade 
gastric lymphomas (Offit et al, 1993). 
I.4.3.2.iii Bcl-10 
Bcl-10 is a newly cloned oncogene, located at lp22 (Willis et al, 1999). It is a 
cellular homolog of equine herpesvims-2 ElO gene. It probably functions as a tumor 
suppressor gene. Wild-type bcl-10 suppresses transformation. Mutant forms showed loss 
of this activity and also gain of flmction transforming activity. MALT lymphomas with 
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lp22 were more aggressive than other low grade MALT lymphomas (Hussell et al, 




II OBJECTIVES OF STUDY 
1. To screen for evidence ofHP and EBV infection in PGL. 
2. To identify any differences in expression of p53 and bcl-2 between 
various subgroups ofPGL. 
3. To investigate the relationship, if any, between p53 and bcl-2. 
4. To study the correlation between p53 expression and genetic abnormalities. 
5. To look for molecular fingerprinting of possible carcinogens in PGL 
by identifying mutations and LOH abnormalities of p53 gene in PGL. 
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III MA TERIALS AND METHODS 
IIL1 Materials 
Forty-six consecutive primary gastric non-Hodgkin's lymphomas O^HL), were 
retrieved from the archive of the Anatomical & Cellular Pathology at the Prince of 
Wales Hospital (PWH), the Chinese University ofHong Kong (CUHK). Deliberately 
excluded from the selection were a few cases ofBurkitt's lymphomas, T cell lymphoma, 
follicular lymphoma and mantle cell lymphomas. Because of their rarity, it would be 
difficult to draw direct comparison. The specimens had been fixed in 10% buffered 
formalin. Selected tissue blocks were routinely processed and paraffin-embedded. All 
the cases originated from the period 1989 to 1998. A clinical database of lymphomas 
had been compiled by Dr. Wing Chan and included information on patient's age, sex, 
tumor size and location. The histological diagnosis was reviewed by Dr. Chan. These 
cases were classified into 17 diffuse large cell lymphomas (DLCL), 15 high grade 
MALT (HM) lymphomas and 14 low grade MALT (LM) lymphomas. DLCL was 
defined as diffuse large cell lymphomas with no history or histological evidence of pre-
or co-existing LM features. HM included all those cases where focal low grade 
component is still identifiable. Among 46 cases, there were 24 females and 22 males, 
ranging in age from 22 to 90 with a median age of 63. The clinical data of the patients 
3 1 
Materials and methods 
were presented in Table HI.1. Each case was histologically examined for presence of 
Helicobacter pylori. One representative tumor block and one normal tissue block were 
selected where available. 
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IIL2 Detection of EBV Latent Gene Product by In-situ 
Hybridization (ISH) 
In-situ hybridization (ISH) is a technique using a labeled single-stranded DNA 
or RNA fragment (probe), whose sequence is complementary to the target. EBV-
encoded RNAs (EBERs) are sensitive marker for EBV infection and abundantly 
expressed in latently infected cells as well as in all latent stages (Rickinson et al., 1996), 
a cocktail of synthetic oligonucleotide was used to probe for EBER by in-situ 
hybridization. 
IIL2.1 Pretreatment of Paraffin-embedded Tissues and 
Apparatus 
Chosen blocks of the formalin-fixed paraffin-embedded tissues were retrieved 
and cut into 4 ^im-thick sections from each case. All the sections were mounted onto 
2% aminopropyltriethoxysaline (APES, Sigma) - coated slides to prevent tissue 
sloughing off. To prevent any RNA contamination, all the apparatus such as storage 
bottles, tanks, cover-slips, forceps and plastic pipette tips were autoclaved prior to the 
in-situ hybridization and the incubation chambers were rinsed with 99% ethanol, 3% 
H2O2, followed by 0.1% diethy pyrocarbonate (DEPC, Sigma) - treated water. 
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IIL2.2 In-situ Hybridization of EBERs 
The tissue sections were allowed to incubate in a 55°C oven for about an hour 
and were deparaffmized in xylene 2 times. They were then rehydrated to DEPC-treated 
water through graded ethanol (99% ethanol — 95% ethanol ~> DEPC-treated water). 
After washing in DEPC-treated water, the sections were pretreated with 200 ^1 of 
3p-g/ml proteinase K (Sigma) in a humid incubation chamber for half an hour at 37 °C. 
The sections were washed in DEPC-treated water and dehydrated in 95% ethanol 
followed by 99% ethanol and air-dried for the next procedure. Then, the hybridization 
was carried out by adding one to two drops of fluorescein-conj ugated oligonucleotide 
cocktail probe (Novocastra, NCL-EBV), and the sections were covered with the 
pretreated coverslips and then incubated at 37 °C for 2 hours. After the hybridization, 
the slides were washed in tris-buffered saline (TBS) with 0.1% Triton X-100 (Sigma) 3 
times to remove the coverslips as well as the probe. For the detection of the 
hybridization, the sections were incubated with rabbit anti-fluorescein antibody tagged 
with alkaline phosphate fNovocastra, NCL-ISH-D) for half an hour at room temperature. 
After washing twice with TBS buffer, the sections were incubated with substrate 5-
bromo-4-chloro-3-indoyl phosphatase and the colorimetric indicator nitroblue 
tetrazolium (BCEPMBT) in darkness for 45 minutes at room temperature. During the 
incubation, the signal intensity was instantly checked under microscope to adjust the 
incubation time for optimal intensity. The sections were fmally counterstained with 1% 
methyl-green progressively. For the interpretation of results, the presence of any dark-
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brown nuclear staining in tumor cells was counted as positivity for EBERs. While rare 
positivity in non-tumor cells was not counted. 
IIL3 Detection of p53 and bcl-2 and LMP-1 Protein 
Expression by Immunohistochemistry 
Li order to detect the protein expression of p53, bcl-2 and LMP-1, monoclonal 
mouse anti-human p53 protein (DAKO-p53, D07; M700) (1:100), monoclonal mouse 
anti-human bcl-2 oncoprotein antibody (DAKO Clone 124, M0887) (1:25) and 
monoclonal mouse anti-human LMP-1 protein (DAKO Clone CS 1-4, M0897) (1:25) 
were used , respectively in immunohistochemical studies. D07 binds to both mutant 
and wild-type p53 proteins, while bcl-2 recognized the inner mitochondrial membrane 
bcl-2 protein. Avidin-biotin peroxidase complex (ABC) method was employed for 
staining of each antibody. The 4 ^im-thick section mounted on APES-coated glass-
slides were prepared for immunohistochemistry. The sections were deparaffinized in 
xylene and rehydrated in graded ethanol (99% ethanol — 95% ethanol — 75% ethanol). 
They were then rinsed in distilled water. Li order to perform antigen retrieval, the 
sections were microwaved in lOmM citrate buffer, pH 6.0 twice for 10 minutes. The 
sections were allowed to cool to room temperature and then washed with distilled water. 
The inhibition of endogenous peroxidase activity was carried out in 0.3% TBS-H2O2 for 
15 minutes and followed by rinsing in distilled water and TBS again. The nonspecific 
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serum binding sites were blocked with 5% normal rabbit serum for 15 minutes. 
Afterwards, excess serum was blotted from sections without washing and then primary 
antibody was applied. For the immunohistochemistry, different antibodies were applied 
respectively on the separate sections and incubated ovemight at room temperature, in a 
humid incubation chamber. For negative controls, the primary antibodies were not 
added in this process. After the primary antibody incubation, the sections were washed 
with TBS for three times, followed by addition of a secondary antibody specific for 
binding the primary antibody added previously. The secondary antibody, that is, the 
biotinylated F(ab')2 fragment of rabbit anti-mouse immunoglobulins (DAKO, E0413) 
(1:200) was applied to the sections and incubated for 30 minutes at room temperature. 
After incubation, excess secondary antibody was washed away with TBS. Amplification 
of immunostaining signal was achieved by the addition of ABC Complex / HRP 
(DAKO, K0355) and incubated for 30 minutes at room temperature. ABC reagent is a 
complex ofthe avidin (glycoprotein) and biotin (linked up with peroxidase) that binds to 
the biotin molecule of the secondary antibody. Afterwards, the sections were allowed to 
wash with TBS for 3 times. The color development was carried out by incubating the 
sections for 10 minutes in peroxidase substrate solution using 0.05% 3,3，-
diaminobenzidine tetrahydrochloride (DAB) as the chromogen. Finally, the sections 
were counterstained with Mayer's hematoxylin, dehydrated through graded ethanol and 
mounted using Permount® (Fisher Scientific SP 15-500). 
For the interpretation of results, brown-stains located inside the nuclei indicated 
positive signals for p53 protein, while brown cytoplasmic-staining indicated positive 
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signals for bcl-2 and LMP-1 protein. Only cases with positive signals in the lymphoma 
cells were regarded as positive, cases with occasional signals in admixed cells e.g. 
epithelial cells, were not counted. The positive signals were scored according to the 
proportion of immunopositive tumor cells as 1+ to 3+. 1+ indicates less than 1/3 of the 
lymphoma cells being stained, 2+ indicates 1/3 to 2/3 of lymphoma cells being stained 
and 3+ indicates more than 2/3 of the lymphoma cells were stained. 
IIL4 Microdissection of Formalin-fixed Paraffin-
embedded Tissues 
Microdissection was employed to procure homogenous cell population for 
subsequent molecular analysis. Li order to increase the tumor-rich tissue from each 
sample and minimize the contamination of tumor by normal tissue, microdissection has 
been used to select areas of tumor from each sample. Twenty serial 5-micron sections 
were cut from formalin-fixed, paraffin-embedded tissues in which the first and the last 
slides were stained with hematoxylin and eosin. These two slides were examined under 
the microscope so as to separate those areas of interest on the sections. Those tumor 
areas were highlighted with a marker pen on the coverslips and they were used as scouts 
for microdissection. The other slides of the serial sections were placed one by one 
above the scouts, and the areas of interests were then similarly marked under each slide. 
All microdissected tissue fragments from distinct tumor parts were removed separately 
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with a sterile scalpel and collected in two different 1.5ml tubes for subsequent DNA 
extraction. 
On the other hand, for the normal control parallel to each case, DNA was 
extracted from another paraffin block with normal gastric mucosa of the same patient 
usually. Also twenty serial 5-microns sections were cut and transferred into 1.5ml tubes 
for subsequent DNA extraction. 
IIL5 Extraction of Genomic DNA from Formalin-fixed 
Paraffin-embedded Tissues 
Genomic DNA was extracted from paraffin-embedded tissues using 
conventional protocol of Proteinase K digestion and phenol/chloroform extraction 
(Sambrook et al., 1989) as well as commercial DNA extraction kit. They are described 
in detail as follows. 
IIL 5.1 Phenol/ Chloroform Extraction 
Genomic DNA was extracted from paraffin-embedded tissues using standard 
protocol (Sambrook et al., 1989). Twenty serial 5-micron sections were microdissected 
and placed into different sterile 1.5ml tubes. For deparaffmization, 1.2ml xylene was 
added and the tubes were incubated at 37 °C for 30 minutes. The tissues were spun 
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down and the xylene was discarded. 1.2ml 100% ethanol was added into the tubes and 
further incubated at room temperature for 10 minutes. This step was repeated once to 
remove residual xylene. After centrifugation, ethanol was removed and the precipitates 
containing tissues were then dried in a DNA Speed-Vac Concentrator (Savant 
Instrument Lic., Farmingdale, NY, USA) for 10 minutes. 1ml digestion buffer 
containing Saline Tris-EDTA (0.1 M NaCl; 0.05 M Tris, pH 7.5 and 1 mM 
ethylenediamine tetraacetic acid [EDTA], pH 7.4), 0.5% sodium dodecyl sulphate 
(Sigma, St. Louis, USA) and 10 mg/ml Proteinase K (Sigma) was added to the 
deparaffinized tissue. The tube was then incubated at 55°C ovemight in a hybridization 
oven with rotation drive on. Additional 10 ^1 Proteinase K was added for 2 or 3 more 
days to ensure complete digestion as indicated by the disappearance of tissue pellet. The 
lysate was divided into two 1.5 ml tubes, with about 400 - 500 i^l each. Equal volume 
of phenol / chloroform / isoamylalcohol (25: 24: 1 in volume, pH 8.0) solution 
(Amresoco, Solon, Ohio, USA) was added into each tube for extraction of protein. The 
tube was reversed up and down gently until a fine white emulsion was formed, followed 
by centrifugation, the mixture was stratified into 3 layers which included an upper 
aqueous layer as well as a lower yellowish organic layer with a thin interface aqueous 
layer contained denatured proteins. The upper aqueous layer containing DNA was 
carefully collected. DNA was then precipitated at - 7 0 � C for an hour by adding 1/10 
volume of 3M sodium acetate (pU 5.2) and 2 volume of chilled absolute alcohol as well 
as 10 mg/ml glycogen solution. The precipitated DNA formed a white pellet was then 
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washed twice with 70% ethanol and dried in a DNA Speed-Vac concentrator. The DNA 
was re-suspended in autoclaved Milli Q water and stored at - 2 0 � C for future studies. 
III. 5.2 Commercially Available DNA Extraction Kit 
Li addition to the conventional protocol, commercially available QDVamp Tissue 
Kit (Qiagen Lic., Hilden, Germany) was also used. Purification ofDNA using QL\amp 
spin column supplied in the kit, requires no phenol/chloroform extraction and alcohol 
precipitation. This kit simplified the procedures of DNA extraction and generated better 
quality of DNA as well as with more consistent yields. After deparaffmization of the 
microdissected tissue, the tissue pellet was resuspend in 180 i^l Buffer ATL (supplied by 
the kit), and 18 mg/ml Proteinase K. The resulting mixture was incubated at 55 °C until 
the tissue is completely lysed. Then, 200^il absolute alcohol was added to the solution 
and mixed thoroughly by votexing. After centrifugation and washing twice with Buffer 
AW (supplied by the kit), the filtrate was discarded. DNA in the spin column was eluted 
twice with 50^il autoclaved MilliQ water that has been preheated to 70 °C. 
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IIL 6 Mutational Analysis of p53 
IIL6.1 Polymerase Chain Reaction - Single Strand 
Conformation Polymorphism (PCR-SSCP) Analysis 
For the screening of gene mutations of p53 gene, Polymerase Chain Reaction -
Single Strand Conformation Polymorphism (PCR-SSCP) analysis was performed. This 
technique is simple and powerful for identifying sequence changes in amplified DNA 
(Orita et al, 1989). It makes use ofDNA,s sequence-specific folding or conformation, 
which determine the electrophoretic mobility of the single-stranded DNA (ssDNA). 
ssDNA with similar molecular weight, but different base sequence will show mobility 
shift. Due to the unpredictable conformational changes and the consequent alterations in 
electrophoretic mobility, different conditions may be required for band separation to 
detect all mutations. 
IIL6.LlPCRPrimers 
Exons 5-8 of p53 gene were included for mutational analysis. Nested PCR-
SSCP was used, to improve the specificity of the amplified target sequences. The 
sequences of both outer and inner primer pairs were listed in Table III.2. The 
oligonucleotide primers were synthesized from Oligos ETC, Inc. (Wilsaville, OR, USA). 
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III. 6.1.2 PCR Amplification of p53 gene 
Nested PCR was performed to amplify Exons 5-8 of p53 gene in which outer 
primer pairs were used in the primary PCR. PCR was carried out in a total volume of 25 
|Lil containing 1 yd ofDNA template, lOpmole of each outer primer pairs, lx PCR buffer, 
2.5 mM MgC12, 0.2 mM dNTPs and 0.5 units of AmpliTaq DNA polymerase (Perkin 
Elmer) and was covered with one drop of mineral oil. It was initiated with activation of 
DNA polymerase at 95 °C for 7 minutes followed by forty cycles of amplification, 
including initial denaturation at 94 °C for 30 seconds, annealing at 55 - 58 °C for 1 
minutes and extension at 72 °C for 1 minute. Finally, the PCR amplification was ended 
with extension at 7 2 � C for 10 minutes. The PCR amplification was carried out in a 
DNA thermal cycler. The secondary nested PCR product for the re-amplification of p53 
gene. The composition of the nested reaction mixtures was similar to that of primary 
PCR except the addition of 2.5^iCi [ a - ^ ^ - dCTP (3000 Ci/mmole, Amersham, 
Buckingham, United Kingdom). PCR amplification was carried out for another 40 
cycles with annealing temperatures ranging from 55-58�C as listed in Table III.2. 
///. 6.1.3 Non-denaturing Polyacrylamide Gel Electrophoresis 
After nested PCR amplification, 5 i^l of secondary nested PCR amplified 
products were mixed with 45 |il of loading buffer containing 0.05% bromophenol blue, 
0.05% xylene cyanol FF (Sigma), 95% formamide and 20 mM EDTA, pH 8.0, and then 
heat-denatured for 10 minutes. Two i^l of the mixture was resolved on a non-denaturing 
polyacrylamide gel with different composition (6% or 8% polyacrylamide gel; 49:1 
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acrylamide: bisacrylamide ratio) with or without 50% glycerol. Gels were run in 0.5 x 
TBE at different conditions such as 3 W at room temperature for 16 — 20 hours or 30 W 
at 4 °C for 4 - 6 hours. Other conditions using various combinations of gel, wattage and 
temperature were conducted to obtain better separation between DNA fragments with 
different conformations (Glavac and Dean, 1993). After electrophoresis, the gel was 
then transferred onto a 3 MM Whatman paper (Springfield Mill, England) and dried 
using the gel dryer (BioRad or Hoofer Scientific Listmments, San Francisco, CA, USA) 
at 80 °C for one hour. The dried gel was exposed to Kodak X-OMAT AR film 
(Eastman Kodak Company, Rochester, NY) at —70 °C or room temperature for 1 — 2 
days. Mutant DNA fragments which appeared as abnormal shifts relative to the normal 
DNA fragments, were further analyzed by DNA sequencing to confirm the mutation. 
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IIL 6.2 DNA Sequencing Analysis 
The DNA sequencing of the normal or mutated allele of p53 gene was 
determined by direct cycle sequencing method which include purification of DNA from 
the normal and abnormal shifts on non-denaturing gel, cycle sequencing as well as the 
denaturing gel electrophoresis. (Sambrook et aL, 1989) 
III.6.2.1 Purification ofDNA from Shifts on Nondenaturing Gels 
For the determination of the sequence of the normal and abnormal shifts on the 
SSCP gel, four or more dots of radioactive PCR products were marked on the SSCP gel 
using a fine needle. After exposure, the corresponding gel position ofthe shifts could be 
relocated according to the signal displayed on x-ray film. Lidividual aberrant shifts were 
carefully excised from SSCP gels and placed into 1.5ml tubes. DNA was eluted with 
50|il Milli Q water with gentle shaking at 65 °C for 6 hours. Two [i\ of eluted DNA was 
re-amplified with the corresponding sets of inner primers using the same conditions as 
described in Section III.6.1.2. The PCR products were resolved on a 10% 
polyacrylamide gel. After electrophoresis, the gel was stained with ethidium bromide 
solution for 20 minutes and was visualized by UV transilluminator. The PCR products 
on the gel were excised and eluted in 500|iil TE buffers at 37°C ovemight. The 
supernatant was then removed and extracted with equal volume of phenol/chloroform 
solution. After centrifugation, the upper aqueous layer was collected and precipitated by 
adding 1/10 volume of 3M sodium acetate and 2.2 volume absolute alcohol. The DNA 
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was pelleted, washed with 70% ethanol，dried and finally resuspended in 10 |iil of 
autoclaved Milli Q water. 
III. 6.2.2 5 'end Label ing of Primers 
One of each primer pairs of the corresponding exons of p53 gene was 
radioactively labeled prior to PCR. Ten picomoles of one primer was labeled with 1 p,Ci 
32 
:Y_ P] — ATP (3000Ci / mmole; Amersham, Buckinhamshire, United Kingdom), 1 x 
polynucleotide kinase reaction buffer and 0.25 units of T4 polynucleotide kinase 
(Amersham) in a total volume of 0.25 i^l. The reaction mixture was incubated for 30 
minutes at 37 °C. 
III.6.2.3 Cycle Sequencing 
DNA sequencing was performed using the Thermosequenase Cycle Sequencing 
Kit (Amersham Life Science Lic., Cleveland, OH, USA) as recommended by the 
manufacturer. Li contrast to the conventional PCR, the principle of cycle sequencing is 
dideoxy-terminating enzymatic chain reaction with either the forward and reverse inner 
primers of the corresponding exon. The labeled primers were subsequently diluted 2-
fold with autoclaved Milli Q water. One microliter of the diluted labeled primer was 
mixed with 2 ^1 template DNA purified from the SSCP gel, 2 |il reaction buffer 
(provided with the kit) and 8 units of Thermosequenase (provided by the kit) in a total 
volume of 17.5^il. 4^il of labeling mixture was transferred to each of the 4 termination 
tubes, labeled as A, G, C and T, each containing 4 i^l of deoxynucleoside triphosphates 
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[dNTP and dideoxyadenoside (1.5 i^M ddA); dNTP and dideoxyguanosine (1.5 i^M 
ddG); dNTP and dideoxycytosine (1.5 i^M ddC); dNTP and dideoxythymidine (1.5 ^M 
ddT) respectively]. The termination reaction mixture was covered with one drop of 
sterile mineral oil and PCR was carried out in a DNA Thermal cycler using same 
conditions as described previously in Table III.2. 
IIL6.2.4 Denaturing Gel Electrophoresis 
After PCR, the reaction was stopped with 4 p,l of loading buffer (provided by the 
kit). The PCR products were heat-denatured for 10 minutes, quickly chilled on ice and 
2\i\ of each termination reaction solution of corresponding samples labeled as A, G, C 
and T were loaded onto an 6% denaturing polyacrylamide gels. 6% polyacrylamide gel 
(29:1 acrylamide: bisacrylamide ratio, BioRad) containing 7M urea was prepared and 
prewarmed at 1650V in 1 x TBE (0.5M Tris, 0.5M boric acid, 0.025M EDTA) for half 
an hour prior to sample loading. Li order to recognize the whole sequence, 
electrophoresis was carried out for 1.5 to 2.5 hours under constant voltage (1650V) for 
different periods, depending on the size ofthe PCR products. After electrophoresis, the 
sequencing gel was then blotted on 3 MM Whatman paper, dried and exposed to Kodak 
film for 1 to 2 days at room temperature or -70 °C. The sequence was read manually 
and compared with the published sequence. 
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IIL 7 Loss of Heterozygosity (LOH) Analysis on 
Chromosome 17p 
Nowadays, the application of PCR with the use of microsatellite polymorphic 
marker is frequently employed to investigate the incidence of loss of heterozygosity 
(LOH). Microsatellites are called simple sequence length polymorphism, or short 
tandem polymorphism. It can be defined as tandem arrays of short stretches of 
nucleotide sequences, usually repeated between 15 and 30 times. (Koreth et al, 1996, 
Weber and May, 1989). Microsatellites belong to the family of repetitive non-coding 
DNA sequences which are widely dispersed in the human genome (Weber, 1990). They 
consist of nucleotide arrays with a repeat size of 2-6 base pairs which are highly variable 
in size but they range around a mean of 100 base pairs. The informativeness of 
microsatellites increases with increasing average number of repeats. There are some 
advantages of microsatellites such as high heterozygosity, ubiquity through the genome 
(especially adjacent to coding sequences) and with PCR typability (Watson et al, 1992). 
A variable locus is made up of a variable number of identical sequences joined together 
in tandem. There are many different variable number tandem repeat loci in the genome, 
so that each individual has his unique pattem of fragments from the variable tandem 
repeat loci. Therefore, the microsatellite PCR method is widely used in most 
allelotyping studies for identifying small regions of change. 
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The repetitive sequences di-, tri-, and tetra-nucleotide repeats are abundant in 
human genome. The nucleotide repeat dA- dC- or cytosine-adenosine (CA)n is one of 
the most frequent sequence motifs in human microsatellites where n varies from 10 to 60 
copies (Weber and May, 1989; Litt, 1991). (CA)n repeats are plentiful throughout the 
human genome, approximately 50 000 — 100 000 separate (CA)n repeat sites are 
estimated to exist and are evenly distributed. (CA)n repeats are located throughout the 
genome at intervals around one every 50 - 100 kilo base pairs with difference in length 
on the patemal and matemal chromosomes (Watson et al., 1992). Because of the 
variable numbers of (CA)n tandem repeats in different alleles of genes, these markers 
are highly polymorphic and thus widely used in PCR based microsatellite polymorphism 
analysis. It can be analyzed quickly by PCR with primers complementary to unique 
sequences adjacent to the repeats. Li informative cases, people who are polymorphic for 
a particular locus will have two different alleles with one from patemal and one from 
matemal chromosomes. These two alleles have different numbers of variable 
dinucleotide repeats at a particular gene or chromosomal region (Koreth et al., 1996). 
The technique of detection of LOH is frequently used for the identification of 
possible tumor suppressor genes (TSGs) (Field, 1996). Li the two-step inactivation of 
TSGs hypothesis, point mutation of a critical suppressor allele is followed by deletion of 
the second allele with total inactivation of tumor suppressor function. Hence, frequent 
presence ofLOH within a particular chromosomal region in a specific tumor may reflect 
this process. LOH analysis is based on detecting differences of the patemal and 
matemal alleles between normal and tumor DNA. If a chromosomal locus is lost in a 
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tumor, one of the two normal alleles w i l l be absent in tumor DNA when compared with 
the normal one. This technique of detection of LOH is superior to the traditionally 
southern blotting technique, as the formerly is highly informative, rapid and simple to 
perform. As it is a PCR based method, even minute amount of DNA, such as that 
extracted from paraffin-embedded tissue sections is sufficient for analysis. 
IIL7.1 Microsatellite Markers 
Five microsatellite polymorphic markers (Table III.3) on chromosome 17p were 
used in the LOH study. Two of the microsatellite markers (D17S1176 and TP53) flank 
the p53 regions, 17pl3.1. The other 3 markers are mapped to chromosome 17pl2-13.1. 
A l l of them were synthesized by MapPairs, Research Genetics Lic., (Huntsville, AL, 
USA). 
III.7.2 PCR Amplification of DNA Fragments Containing 
Polymorphic Microsatellites 
The PCR amplification of the microsatellite polymorphic markers of both the 
normal and tumor samples was performed in a total volume of 5 [il reaction mixture 
containing 1 ^il genomic DNA extracted from paraffm-embedded tissues. In detail, one 
of each primer pairs, usually the forward primer, was 5, end labeled with [y-^^P] - ATP 
by T4 ploynucleotide kinase, as described in Table m . 3 . The ^^P labeled forward 
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primer (lOpmoles) was then mixed with the unlabeled reverse primer (lOpmoles) o f the 
corresponding marker, 1 x PCR buffer, 2mM MgCl2, 1.25mM deoxyribonucleoside 
triphosphate (dNTPs), and 0.625 units of AmpliTaq Gold D N A polymerase (Perkin 
Elmer Applied Biosystems, Norewalk，CT). Each tube was covered with one drop of 
sterile mineral oil. PCR reactions were performed in a DNA thermal cycler (Perkin -
Elmer model 480) with the following steps: an initial denaturation at 95°C for 12 
minutes to activate AmpliTaq Gold DNA polymerase followed by 40 cycles of 
amplification (1 minute denaturation at 94 °C，30 seconds annealing at 52 - 55。C and 30 
seconds polymerization at 72 °C). Finally fmish with a 10 minutes extension step at 
72°C. 
IIL 7.3 Denaturing Polyacrylamide Gel Electrophoresis 
The reaction was stopped by adding 15^il loading buffer. PCR products were 
heat-denatured at 95 °C for 10 minutes, quickly chilled on ice and separated by 
electrophoresis in a 6% polyacrylamide (19:1) / 7M urea denaturing gel under constant 
voltage (1650V) for different period according to the size of PCR products. The 
preparation of gels and the subsequent procedures for electrophoreis have been 
described in Section IIL6.2.4. 
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III. 7.4 Determination of Allelic Abnormalities 
Several allelic abnormalities, such as loss of heterozygosity and microsatellite 
instability, could be detected by microsatellite analysis. L O H was inferred by at least 
30% reduction in allele signal intensity in the tumor samples relative to that of matched 
normal samples. The matemal and patemal alleles were visualized as 2 distinct bands 
on the autoradiograph. However, as slipped-strands mispairing sometimes occurred 
during PCR amplification, sutter bands with weaker intensities were occasionally 
observed. Nevertheless, the assessment of the allelic intensities was based on the signal 
intensities of the 2 major distinct bands. When the allelic intensities and patterns of the 
patemal and matemal alleles in both normal and tumor DNA were similar, this was 
referred as retained of heterozygosity (R). When the number of CA repeats was similar 
or equal in both the patemal and matemal alleles, the 2 bands could not be distinguished 
and this was considered as non-informative (NI). Microsatellite instability was 
confirmed by the presence of allelic shift, allelic expansion and novel allele. 
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III.8 Statistical Analysis 
Pearson's chi-square test and Spearman's correlation were applied for the 
statistical analysis in this study. Fisher's Exact test was used instead of chi-square test 
when expected count is less than 5. The data was processed using version 8.0 o f the 
Statistical Package for Social Science (SPSS 8.0).户-value less than 0.05 (95% 




IV.1 Association with Helicobacter Pylori (HP) 
Thirty- five of the 46 lymphomas were positive for Helicobacter pylori. These 
included all 29 (100%) M A L T type lymphomas ofboth low grade and high grade. Only 
2/10 (20%) ofthe EBV+ DLCL and 4/7 ofthe EBV- DLCL were HP+. The results were 
summarized in Table IV.1. 
IV.2 Detection ofEBERs by ISH 
Al l the cases were examined for EBERs by in-situ hybridization. EBERs were 
detected in 10 of 46 cases (21.7%) in which all of them are DLCL (Figure L4B). 
EBERs were not found in any of the H M and L M lymphomas. A summary of the 
EBERs detection is provided in Table IV.1. 
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IV.3 Immunohistochemical Analysis 
IV.3.1 Protein Expression ofEBVLMP-1 
Al l EBV+ DLCL were examined for LMP-1 expression by 
immunohistochemistry. Three (30%) showed positive reaction. Ln all three cases, the 
number of positive tumor cells amounted to less than 33%. The results were shown in 
Table IV.1. 
IV.3.2 Protein Expression ofp53 
Forty-five cases (1 cases which were exhausted of tissues) were examined for 
p53 protein expression by immunohistochemistry. For DLCL, 15 of 16 cases (94%) 
were found to express p53 protein (Figure IV.5B.). A l l EBV+ DLCL (100%) showed 
p53 expression. In the HM group, p53 were detected in 11 of 15 cases (73%) (Figure 
IV.1.) LM had only 1 out of 14 cases (7%) with p53 protein expression. When 
compared with the high grade tumors (DLCL and HM), LM showed a significantly 
lower rate of p53 expression (p<0.01). The results were listed in Table IV.1. 
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IV.3.3 Protein Expression of bcl-2 
A l l cases except 1 EBV+ DLCL (was not done due to exhaustion of tissue) were 
examined for bcl-2 protein expression by immunohistochemistry. A l l cases (100%) of 
L M expressed bcl-2 protein (Figure IV.2A). In DLCL, 6 of 16 cases (41%) were 
positive for bcl-2 protein and the remaining 10 cases were negative for bcl-2 protein 
(Figure IV.5A). Amongst the EBV+ DLCL, only 2 (22.2%) expressed bcl-2. Amongst 
the HM, overexpression of bcl-2 was found in 5 of 15 cases (33%) (Figure IV.2B and 
2C). The results were summarized in Table IV.1. 
IV.3.4 Correlation between p53 and bcl-2 Protein Expression 
An inverse relationship between p53 and bcl-2 expression is observed in the L M 
and EBV+ DLCL (r = -0.327, p = 0.028). Among the LM, only one case showed both 
bcl-2 and p53 protein expression. The remaining 12 (92.3%) cases were p53 - and 
bcl-2 +. In those 10 EBV+ DLCL, 7/9 cases (77.8%) exhibited p53 + and bcl-2 -
phenotype. Amongst the remaining EBV- high grade tumors 54.5% were also found to 
exhibit an inverse relationship viz. either p53 + / bcl-2 - or p53 - / bcl-2 +. The results 
were summarized in Table IV.1. 
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IV.4 Mutational Analysis of p53 
A l l 46 lymphomas were examined for p53 mutations in exon 5 to 8 by PCR-
SSCP followed by direct DNA sequencing. Mobil i ty shifts were identified in 24 cases 
by SSCP analysis. Direct sequencing of the aberrantly migrated DNA bands revealed 
nucleotide changes with different kinds of mutations including missense, stop, splicing 
and silent mutation. Mutations were detected in 8 ofthe 10 (80%) EBV+ DLCL, 1 ofthe 
7 (14.3%) EBV- DLCL, 6 of 14 (42%) L M and 9 of 16 (60%) HM. In 12 cases, more 
than 1 mutation (in the same exon or in different exons) was detected. The results were 
shown in Table IV.2. and IV.3. 
Both cases DL3 and DL4 of the DLCL were found to carry up to 4 mutations in 
different exons. ln DL3, one missense mutation was detected in exon 5, one silent 
mutation in exon 7 as well as in exon 8 and also one splicing mutation in intron 8. L i 
DL4, a missense mutation was detected in exon 5. L i addition, 2 missense mutations 
and 1 silent mutation were also found in exon 7. No mutation of exon 6, introns 6 and 7 
(Figure IV.6.) was found in the DLCLs. Mutations in intron 8 were only found in 
DLCLs, 2/3 involved nucleotide position 14115. Futhermore, 7 of the 8 EBV+ DLCL 
harbored mutations of exon 7 QFigure IV.7.) whilst 5 of them had changes in exon 5. 
Four cases of EBV+ DLCL had mutations involving codon 242 of exon 7 (Figure 
IV.8.). L M and H M had mutations in the similar distribution. 
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IV.5LOHAnalysis on Chromosome 17p 
Twenty-five cases including 10 DLCL, 7 H M and 8 L M were examined for L O H 
on chromosome 17p. The results are summarized in Figure IV.9. 
LOH analysis found abnormalities in 8 of the 25 cases including 4/5 EBV+ 
DLCL, 0/5 EBV- DLCL, 3/7 H M and 1/8 LM. Microsatellite instability was detected in 
3 ofthe EBV+ DLCL and 1 HM. Allelic loss was noted in 2 EBV+ DLCL, 2 H M and 1 
LM. Representative LOH results of those cases with abnormalities were shown in 
Figure IV.10. and Figure IV.11. 
Furthermore, the EBV+ DLCL with LOH abnormalities included DL7 and DL9, 
the two cases negative for p53 mutations by SSCP screening ^Figure IV.12.). However, 





V. 1 Helicobacter Pylori Association 
Low grade primary B cell gastric lymphomas of the stomach with features 
resembling musosal associated lymphoid tissue (MALT), as typified by Peyer's patches 
of the small intestine, were first described by Isaacson and Wright in 1984. Since then, 
M A L T type lymphomas have become widely accepted as a distinct entity with an 
indolent course, confined to the stomach and immediate draining lymph nodes for many 
years before disseminating to other sites. The paradox of a lymphoma arising in the 
gastric mucosa, in which no organized lymphoid tissue is normally present, has been 
explained by the finding that development o f M A L T type features in the gastric mucosa, 
as a response to infection by HP. L i recent years, the concept has been extended to the 
high grade gastric lymphomas. Some people made the assumption that all these high 
grade lymphomas arose from transformation of the low grade M A L T lymphomas. 
Others like us, however, have found evidence to suggest the presence of two distinct 
groups of high grade lymphomas. One group (we term DLCL) showed no evidence of 
pre- or co-existing low grade components and are negative for mucosal receptors e.g. E-
Selectin, V -CAM and integrin a4p7. The other group (we term HM) expressed mucosal 
receptors and had changes o fLM. 
5 8 
Discussion 
Our study found presence o f H P in 100% of the gastric M A L T lymphomas of 
both low and high grade. This finding was close to that reported by Isaacson (1996) in 
which HP was identified in over 90% of gastric M A L T lymphomas. This suggests that 
HP infection may be an important etiologic factor in the development of M A L T 
lymphomas. 
The two DLCL groups combined were HP+ in only 6/17 (35%) cases. Only 2/10 
(20%) o f E B V + DLCL were HP+, while 57% of the EBV- DLCL were HP+. L i Hong 
Kong HP is detected in 57% of benign endoscopic gastric biopsies (Chan et al, 1991). 
The EBV+ DLCL have therefore a lower than average HP+ rate whilst the EBV- DLCL 
has no increased association with HP. This suggests that HP is unlikely to play a 
pathogenic role in DLCL. 
It is thought that HP might provide the antigenic stimulus critical for growth of 
the lymphoma. Many studies also showed that eradication of HP could lead to 
regression of low grade gastric M A L T lymphoma. It was suggested that the genetic 
damage acquired was insufficient to allow independent proliferation in M A L T 
lymphoma. HP infection stimulated T- helper cells to produce growth factors needed for 
the lymphoma cells (Calvert et al., 1995). 
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V.2 Association with EBV 
EBV was first linked to Burkitt's lymphoma of the African and non-African 
types. En Southern China and Hong Kong, it is associated with nearly all cases of 
nasopharyngeal carcinoma fNPC) and most of the sino-nasal lymphoma. (Young et al., 
1986; Lung et al., 1989) The association o f E B V with NHLs, especially in extranodal T 
cell NHLs, is in general stronger in our locale, indeed in much of Asia, than in the west. 
Part of this is due to the higher incidence of extranodal T cell NHLs in Asia (Chan et al., 
1994a; Peh et al, 1995). The EBV positivity rate in our series of gastric lymphomas 
(21.7%) is similar to the previous study in Hong Kong in which 18% of lymphomas 
carried EBV (Hui et al., 1994), but somewhat higher than the 11% in Korea (Lee et aL, 
1997). Further more, all the EBV+ tumors were DLCL, accounting for 58.8% of the 
group. This again is similar to that previously observed by Hui et al. (1994). Notably, 
all H M and L M were negative for EBV. Gaidano et al. (1997a) included 19 gastric 
MALT lymphomas in their series and all ofthem were also negative for EBV. 
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V.3 Protein Expression of p53 and bcl-2 
V.3.1p53 
The immunohistochemical expression of p53 protein has been detected in 10-
40% o f N H L (Pezzella et aL, 1993; Cooper and Haffajee, 1997; Kramer et al, 1996). 
p53 overexpression is found to correlate with higher histological grade of the lymphoma 
and poorer rate of remission and / or survival (Cooper and Haffajee, 1997; Hazar et al., 
1997). L i our study, p53 protein expression is found in 60.9% of the 46 gastric 
lymphoma which is considerably higher than those reported with 17% of gastrointestinal 
NHLs (Hazar et al., 1997) and in 20% of gastric M A L T lymphomas (Nakamura et al., 
1996). The higher rate found in our study partly reflects the fact that more high grade 
lymphomas (69.6%) are included in our study. Overexpression of p53 was found in 
83.9% of the high grade lymphomas (including all the cases EBV+ DLCL, 85.7% of 
EBV- DLCL and 73.3% o f H M ) and 7.1% ofthe LM. These figures are not significantly 
different from those reported by Martinez-Delgado et al. in 1997. The latter group 
reported p53 expression in 80% ofhigh grade and 18.2% of low grade lymphomas (but 
their series included only 16 cases of gastric lymphomas). 
A l l the EBV+ lymphomas showed p53 over-expression compared with 50% of 
the EBV- lymphomas (p<0.01). A recent report on gastric carcinoma in Hong Kong 
(Leung et al., 1998) found that the p53 expression of EBV+ carcinomas were more 
likely to be weaker than the EBV- carcinomas. Qualitatively, 35.3% ofthe p53+ EBV-
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high grade tumors showed 3+ strong positivity compared with only 1 case (11.1%) of 
the EBV+ DLCLs. One possible explanation is that presence of EBV associated 
proteins, may interfere with the antibody sensitivity. 
V.3.2Bcl-2 
As for the immunohistochemical expression ofbcl-2 protein, it has been reported 
in almost 100% of the follicular lymphomas, while only 21% of nodal B-cell DLCL 
express bcl-2 protein (Monni et al, 1996). The frequency of bcl-2 positivity in B-cell 
lymphoma significantly decreased as the histological grade advanced. Our results 
confirm this observation. The positivity rate of bcl-2 protein expression in all L M 
lymphomas and 35% of the high grade lymphomas (with some differences between the 3 
sub-groups with 22% bcl-2 positivity in EBV+ DLCL, 57.1% of EBV- DLCL and 
33.3% o f H M ) in our study. Furthermore, the low grade component ofthe H M were all 
bcl-2 positive. This is similar to the results reported in western and Japanese series, with 
90-100% L M lymphomas (Ashton-Key et al., 1995) and 44% of high grade gastric 
NHLs OMakamura et a/.,1996) expressed bcl-2. Although one series O^arvatil et al., 
1995) found no bcl-2 expression in high grade lymphomas ofthe GI tract. 
However, the meaning of bcl-2 expression is not clear. As a control, a series of 
10 gastric biopsies with diagnosis ofbenign HP+ or HP- gastritis were examined for bcl-
2 expression OFigure IV.3.), it was found that bcl-2 expression was detected in the 
mucosal lymphocytes in all 10 cases. The bcl-2 positive lymphocytes include a mixture 
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of mantle cells (around reactive follicles, reactive T-cells and B-cells as well as plasma 
cells (Figure IV.4.). This is not an unexpected finding since studies on gastric 
carcinomas have often mentioned bcl-2 positivity in the tumor infiltrating T 
lymphocytes and the lymphocytes of the benign gastric mucosa (Gulley et al., 1995). 
Moreover, previous molecular studies on L M had yielded no evidence of bcl-2 gene 
rearrangement (Horsman et al., 1992, Leroux et al, 1993). I f bcl-2 expression is part of 
the normal phenotype of the gastric mucosal lymphocytes, the 100% positivity in L M is 
ftnther evidence to support that L M arises from the gastric mucosal lymphocytes. 
KJ.J Correlation between p53 and bcl-2 Expression 
The oncosuppressor gene p53 plays an important role in normal cell physiology, 
regulates the Gl-S phase transition in the cell cycle and controls cellular proliferation by 
inducing apoptosis. The expression of bcl-2 oncoprotein blocks apoptosis and 
immortalize the B cells in follicular lymphoma. Simultaneous accumulation of 
functional bcl-2 oncoprotein and lack of functional p53 protein provide a synergistic 
effect on survival advantage of tumor cells. An inverse relationship of p53 and bcl-2 
found in 92.9% ofLM as well as 77.8% ofthe EBV+ DLCL is noted. Our finding agrees 
with the previous reports by Pezzella et al. and Nakamura et al. However, most 
researchers have failed to demonstrate genetic aberration to support the 
immunohistochemical evidence of bcl-2 and p53 overexpression. Southern blot studies 
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for bcl-2 gene rearrangement could not be performed in the present study because too 
few cases had sufficient amount of firesh tumor tissue. 
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V.4 p53 Gene Molecular Analysis 
Mutation ofthe p53 gene is the most frequent alteration found in human cancers. 
There had been a few mutational "hot spots" recurring in certain cancers. Amongst 
them, codon 249 was found in hepatocellular carcinoma, (Hsu et al, 1991, Bressac et 
al., 1991, Scorsone et aL, 1992). A more recent focus of interest is the codon 72 
polymorphism, either arginine or proline at this residue. Homozygosity for Arg-72 
represents a significant risk factor (seven fold that ofheterozygotes) in the development 
of cancers associated with human papilloma vims, especially cervical cancers (Helland 
et al., 1998; Storey et al., 1998; Lanham et al., 1998; Rosenthal et al., 1998). On the 
other hand, homozygous Pro-72 is associated worse prognosis in female lung cancer 
patients (Wang et aL, 1999). Litronic mutations ofp53 gene had been found to result in 
splicing errors which affect the final protein function (Takahashi et al, 1990, Kikukawa 
etal., 1998). 
The frequency of mutations in lymphoid malignancies is in general low, 6/45 
and 8/94 in 2 series (Park and Lee, 1998, Martinez-Delgado et al., 1997) but varies in 
different histological groups. Mutations of p53 had been associated with high grade 
transformation of follicular lymphoma (Sander et al, 1993; Lo Coco et al., 1993). In 
MALT lymphomas, p53 mutations were detected in two of 16 H M whilst all 33 L M in 3 
different series were negative (Gaidano et al, 1997b; Martinez-Delgado et al., 1997). 
However, in the large series of 60 gastric MALT lymphomas from Du et al. (1995), 18 
(30。/。) were found to have p53 mutations. Of these, 9 were L M and 9 were HM. They 
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also noted an increase in LOH rate from L M to HM. In one series (Park and Lee, 1998), 
of three gastric lymphomas (1 EBV+DLCL, 1 EBV-DLCL and one EBV- difflised 
mixed type), only the EBV+ DLCL showed a p53 mutation in exon 7. 
Our results show a significant number of p53 mutations detectable within the 
conserved regions in exon 5-8, with or without p53 expression. A total of 24 out o f46 
lymphomas (52.2%) were found to have p53 mutation. Mutations were detected in all 
groups, with the highest percentage (80%) found in EBV+ DLCL groups and the lowest 
in EBV- DLCL (14.3%). EBV+ gastric lymphomas had significantly higher rate ofp53 
mutation than EBV- gastric lymphomas (p<0.05). In addition, there were more than one 




V.5 Distribution of p53 Mutations and Molecular 
Fingerprinting 
L i the 8 cases of EBV+ DLCL with p53 mutations, 7 cases (87.5%) had 
mutations in exon 7, 4 cases (50%) in exon 5 and 3 cases in intron 8. Comparing the 8 
EBV+ DLCL and 16 EBV- gastric lymphomas, mutations ofexon 7 are significantly ^p< 
0.002) more frequent in EBV+ gastric lymphomas (87.5%) than the EBV- gastric 
lymphomas (18.8%). The only case o f E B V + gastric DLCL reported by Park and Lee 
(1998) was also noted to harbor mutation in exon 7, though sequencing result was not 
given in their paper. There were 2 cases (DL3 and DL4) with 4 mutations. Recurrent 
mutation of nucleotide position 14115 in intron 8, was found in DL3 and DL6. 
Mutations involving codon 242 of exon 7 were seen in 4 cases (50%). The significance 
ofthis is unknown, as in 3 cases the amino acid residue remained unchanged. However, 
this codon may mark a mutational hotspot for EBV+ DLCL. Polymorphism of this 
codon may be associated with increased risk of developing this unusual group oftumor. 
The frequency of p53 mutations is higher in H M (60%) than L M (42%). 
However, the distribution of the mutations shows considerable similarity between these 
two groups. They share the recurrent intron 7 splicing mutation at nucleotide position 
13450, mutations involving intron 6 and exon 6. These 3 features are absent in the 
DLCL. Four of the 15 (26.7%) MALT type lymphomas with p53 mutations had 
mutation in exon 6 and 6 (40%) had mutations in exon 8. Jn Du et al.，s study (1995), 
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exon 6 was the commonest site of p53 mutation. Our result agrees with that o f D u et al. 
(1995). It seems plausible that H M arises from transformation o f L M . The accumulation 
ofp53 abnormalities is associated with tumor progression. 
Apart from p53 mutation, allelic loss or microsatellite instability (E^) of p53 
gene were also significant in the development of lymphomas (Du et al., 1995; Peng et 
d； 1996; Chong et al., 1997). Our results found microsatellite instability in 3 o fEBV+ 
DLCL and 1 HM. L i addition, 5 cases with allelic loss were also detected in different 
groups. Only 1 L M (7.1%) showed allelic loss. A l l the remaining p53 abnormalities in 
the LOH analysis of chromosome 17p belonged to high grade lymphoma. This shows 
that more genetic abnormalities are associated with the high grade tumors as previously 
suggested by Du et al. (1995). LOH within p53 gene region (17pl3.1) was relatively 
infrequent and found only in 1 single case o f E B V + DLCL. However, LOH of nearby 
chromosomal region (17pl2-13.1) was detected in 4 EBV+ DLCL, 3 H M and 1 LM. 
Although, a number of the detected mutations does not cause alteration in the 
p53 protein (silent mutations, intronic mutations further away from the exons), the 
distribution of the mutations may be a form of molecular fingerprinting of the 
carcinogen involved. The differences in distribution of p53 mutations between EBV+ 
DLCL and the M A L T lymphomas, as mentioned above, suggest that these two groups of 
gastric lymphomas have different carcinogenic factors. The similarity between L M and 
H M on the other hand, suggest a common carcinogen. 
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K(5 Possible Role of p53 Mutation in EBV+ Gastric 
Lymphomas 
It is well known that p53 protein interacts with viral proteins of many DNA 
vimses, including the simian virus 40T antigen, adenovirus E lB , and human 
papillomavirus E6 (Keiss et al., 1993). The EBV viral protein EBNA-5 had been shown 
to bind to p53, though the significance of this interaction had not been identified 
(Szekely et al., 1993). In addition, the EBV viral protein, BZLF-1 interacts with p53 
and inhibits p53-dependent transactivation. BZLF-1 initiates the switch in EBV from 
latent to lytic form infection and would be inhibited by the overexpression of p53 
(Zhang et al., 1994). Furthermore, another protein encoded by EBV, LMP-1 (latent 
membrane protein) had been found to inhibit p53 mediated apoptosis (Okan et al., 
1995). In follicular lymphomas, bcl-2 was thought to play an important role in the 
immortalization ofthe tumor cells, the low bcl-2 expression makes this role unlikely in 
EBV+ DLCL. Although the mechanism for p53 up-regulation in EBV+ DLCL is not 
certain, considering the low LMP-1 positivity, it is unlikely to be related to LMP-1 in 
most cases. Li most tumor studies, p53 overexpression only rarely corresponds to p53 
gene abnormalities. In our study, we detected an impressive 100% association between 
p53 mutations and / or LOH abnormalities with overexpression in EBV+ DLCL. It is 
possible that mutations of p53 gene itself and other genetic abnormalities in the nearby 
region (as shown by LOH abnormalities) may be important in the loss ofgrowth control 
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in these tumors. The relationship of the abnormal p53 gene with other EBV related 
genes such as EBNA-5 and BZLF-1 is unknown. The strong association with p53 exon 7 
mutations in EBV+ DLCL, may suggest possible EBV (induced mutations) 
susceptibility in this region, especially at codon 242. Alternatively, mutation of this 
location leads to changes in p53 protein with synergistic effect on EBV's transforming 
potential. A transfection experiment with specific exon 7 mutations introduced into 
lymphoid cell lines through plasmids, to test transforming susceptibility in the presence 
























































































































































































































































































































































































































































































































































































































Table III.1 Clinical data of all the cases 
Case Sex Age Diagnosis Specimen Type* Site Tumor Size 
DL1 F 52 DLCL — TG — Antrum 6.5 ~~ 
DL2 M ~ 39 — DLCL TG — Antrum — 3 
DL3 F ‘ 75 — DLCL Bx NA 8 
~ D L 4 F 83 DLCL SG Body H 
DL5 M 78 DLCL — TG 一 Antrum — 8 X 5 — 
DL6 F 52 — DLCL SG — Anterior — 6 
DL7 M ~ 42 — DLCL SG Antrum — 5 
DL8 M ~ 73 ~ DLCL SG — Body ~ " 3.2 
DL9 M 一 54 DLCL — TG — Lesser Curve — 6 
DL10 F — 63 “ DLCL 一 TG 一 Lesser Curve — 6.5 X 8.2 
DL11 F — 48 “ DLCL TG — Lesser Curve 9 ~ 
D L 1 2 ~ F • 68 DLCL “ DPG “ Body 1 
D L 1 3 ~ M • 71 DLCL “ SG “ Body 8 
DL14 M ~ 72 — DLCL Bx Lesser Curve 6 
~~DL15 F 77 DLCL DPG Pylorus 2 .2X2 
DL16 F 83 — DLCL Bx ~ L e s s e r Curve _ NA 
DL17 F 78 DLCL TG Antrum 9x7.5 
H1 F “ 90 HGM “ Bx = NA NA 
H2 M “ 29 — HGM “ DPG “ Pylorus 2.8 
H3 F - 58 一 HGM Bx Antrum 0.7 
H4 F - 81 — HGM “ SG “ Posterior 1 
H5 F “ 32 — HGM “ DPG Incisura 1.5 
H6 F — 74 HGM — Bx 一 Lesser Curve — 2 
H7 M ~ 51 ~ HGM Bx Incisura 5 
H8 F “ ^ 5 6 HGM ’ TG Polyagastrectpmy 
Anastomosis .J_ 
H9 M M HGM DPG Antrum i l 
H10 F — 66 HGM 一 TG 一 Body 一 Diffuse 
Hl l “ M ~ 4 0 HGM TG Cardia 4 
H12 — M — 70 HGM — SG Antrum • 5 
H13 F • 77 — HGM “ SG — Posterior 6 
H14 F 57 — HGM SG Greater Curve “ 10 
H15 M 63 HGM TG Antrum 2.5X3.7 — 
L1 M 64 LGM — Bx — Anterior — 3 
L2 M 44 — LGM SG Antrum Difflise 
L3 M 56 LGM DPG Anterior Diffuse 
L4 M 41 LGM SG Lesser Curve 1.5 
L5 M 52 LGM Bx Anterior 0 8 
L6 M 36 LGM DPG ~ Posterior 1 
L7 F 22 — LGM Bx Posterior NA 
L8 M 84 LGM Bx NA ^ 
L9 F 54 一 LGM Bx Prepyloric “ NA 
LlQ M 72 LGM Bx Antrum “ 6 
Ll l M 72 LGM — SG B ^ 0 
L12 M 76 LGM SG ~ L e s s e r Curve 7 
L13 F 76 LGM Bx Fundus ^ 
" ^ ^ F ^ ^ ^ TG Anterior J T s 
*TG: Total gastrectomy; SG: Sub-total gastrectomy; DPG: Distal partial 
gastrectomy and Bx: Biopsy 
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Table III.2 Primer sequences of p53 gene and PCR conditions used for 
PCR-SSCP analysis 
Exons Product PCR Conditions Primers Sequences* 
Size (bp) Annealing Temp. / 
No. of Cycles 
Outer ~~ 
Primers 
5 m 550C/ f : 5'-TGTTCACTTGTGCCCTGACT-3' 
40 r: 5'-AGCAATCAGTGAGGAATCAG-3' 
6 ^ 55。C/ f: 5'-TGGTTGCCCAGGGTCCCCAG-3'~~ 
40 r: 5 ‘ -GGAGGGCCACTGACAACCA-3 ‘ 
7 ^ 55°C/ f: 5‘-CTTGCCACAGGTCTCCCCAA-3‘~~ 
40 r: 5'-AGGGGTCAGCGGCAAGCAGA-3' 
8 445 58°C/ f : 5'-TTGGGAGTAGATGGAGCCT-3' 
40 r: 5 ‘ -AGTGTTAGACTGGAAACTTT-3 ‘ 
Inner 
Primers 
5 ^ 55°C/ f: 5'-TTCAACTCTGTCTCCTTCCT-3' 
40 r: 5，-CAGCCCTGTCGTCTCTCCAG-3’ 
6 m 550C/ ~ ~ f : 5'-GCCTCTGATTCCTCACTGAT-3‘ 
^ r: 5,-TTAACCCCTCCTCCCAGAGA-3’ 
1 r ^ 55。C/ f: 5,-AGGCGCACTGGCCTCATCTT-3,~~ 
40 r: 5'-TGTGCAGGGTGGCAAGTGGC-3' 
8 2 ^ 58。C/ f: 5'-TTCCTTACTGCCTCTTGCTT-3' 
40 r: 5'-AGGCATAACTGCACCCTTGG-3' 


































































































































































































































































































Table IV.1 EBER and protein expression of all the cases 
Case a « g g ^ 6 ^ H M r y 3 s ^ f e i ! a ? ^ & _ : : ; i ; ! i « m i “ 
‘DL1 - N P — 2+ — N N 
“DL2 - P P 1+ — N N 
—DL3 — N P 1+ N N 
“DL4 — N P ND — ND N 
—DL5 N P 1+ N N 
“DL6 N P — 2+ N P 
一 DL7 一 N P 2+ N P 
“DL8 ~ N P 1+ — 2+ P 
“DL9 - P P 2+ — 3+ N 
一 DL10 — N P 3+ N N 
“DL11 — P N 一 1+ — N 
—DL12 — N N 3+ N 
“DL13 — N N — N — 3+ 
DL14 P — N “ 1+ “ 1+ “ 
“DL15 — P N — 2+ 3+ 
“DL16 — P N ~ 3+ — 3+ 
DL17 N N K N 
~ H1 P N 3+ N 
—H2 ~ P ~ N 1+ — N — 
“H3 — P N — N — N 
• H4 — P N — 3+ 一 3+ 
—H5 — P N N ~ ~ N 
H6 — P N — N — N 
“H7 一 P N — 2+ — N 
“ m — P N — 1+ — N 
H9 — P — N — 2+ 3+ 
• H10 — P N — 3+ ~ N 
Hll — P N — 2+ — 2+ 
“H12 — P N 一 1+ — N 
• H13 — P N — 3+ — N 
“H14 — P N — 2+ — 2+ 
H15 P N N 3+ 
— L 1 一 P N N ‘ “ 3 + 
12 一 P N — N — 2+ 
L3 一 P N N ~ 3 + ~ 
L4 ~ P N — N — 3+ 
L5 — P N — N — 3+ 
L6 — P N — N — 3+ 
L _ ^ z _ _ ^ p N Z Z l i _ _ Z I I I 
L8 ] Z J Z I _ _ j L Z Z _ j ± _ I Z _ j ± _ — 
L9 一 P N — N — 2 + 
U 0 “ P — N “ N ‘ 1 + 
Z _ M J _ Z h N Z Z ^ ^ I ^ Z l 2 ^ Z 
L12 ~ P — N — N — 2+ “ 
'_JJJ_^_X N KZZZUL 
I L14 P N N ~~~3+ 
75 
Table IV.2 Results of mutational analysis of p53 in diffuse large cell 
lymphomas 
Case Exon Position Condon Nucleotide change Type of 
mutation 
DL1 1 13066 m CTC(Leu)<>TTC(Phe) Missense ;^:¾:;¾::;:¾¾^ 
^^^^^^^^^^^^m^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^X 
DL2 7 14053 242 TGC(Cys) <> TGI(Cys) Silent 
Intron 8 14112 CAGgtcagg ^ CAGgttagg Splicing 
DL3 5 13092 138 GCC(Ala) <^GAC(Asp) Missense 
7 14053 242 TGC(Cys) <>TGI(Cys) Silent 
Intron 8 14115 CAGgtcagga «=i>CAGgtcagaa Splicing 
8 14551 294 GAG(Glu) <>GAA(Glu) Silent 
DL4 5 13220 181 CGC(Arg) ^TGC(Cys) Missense 
7 14053 242 TGC(Cys) ^TGI (Cys) Silent 
7 14077 250 CCC(Pro) <> ACC(Thr) Missense 
7 14093 256 ACA(Thr) <>GCA(Ala) Missense 
•DL5 、 ;5, ,〉,,:13_、,,/:卿):,:,::,:\ cm^^,<m^m-\i- mmf£' 
,；、,7, A ;: 140½:..:雄：：‘彳：.；_ ; C k ? e 6 G i # ’ : ' ( | _ ( ( | ! _ ; ^ ^ ( ; 纽 _ ?『急 
DL6 7 14052 242 TGC(Cys)OTAC(Tyr) Missense 
Intron 8 14115 CAGgtcagga ^CAGgtcagaa Splicing 
^DL8 ,、: ” 7 : / ' : : 1 輕 _ ) : ' : : 。 、 ' : _ : _ 領 嚇 _ ’ ' _ ( _ ; ' . ¾ - ¾ ¾ ^ ¾ ! 
- - - 、’’… --、-'-�''• ----- ,:,'~勺：’么/', ','¾',",:" ,、 <'?�.,w.,j.,,>‘,/,/,,.:..,,jt':。％~j.\ 
DL10 7 14012 229 TGT(Cys) <> CGT(Arg) Missense 
P m ^ 14512 281 ；： OAaAsp)：^ GASAsp>：'^ '^ :tV,.i" SileW# ^ ¾ 
：:-.• - ；- - 。：、 - -、- , 、'，’’" • , . ": ''': '',: ‘ ''. .-.= -,¾' - -*；-'-；' .".-l-,r'' '-', '/-S:,->^':'Z-^'J:/ 
8 14589 307 GOT(Gi^ ^GTT(Val)5： ;； fKssensfe； ： 
‘, ‘ ‘ ‘ ‘/ .,',.'',‘,‘‘‘',''',,, 
- - - - - • „. ““ -, •:.;••,,-.. •••：-•/ ','/' '；"； ；/hv/< 
l_ “ “ ‘ 1丨丨 •… •! , ‘ ‘‘ '“‘ ‘ ‘ ‘‘ - ' ' , , ''"' <• /々 ， 
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Table IV.3 Results of mutational analysis of p53 in MALT lymphoma 
Case Exon Position Condon Nucleotide change Type of 
mutation 
^ 6 13322 m CTG(Leu)^TTG(Leu) Silent 
7 14046 240 AGT(Ser)^AAT(Asn) Missense 
7 14098 257 CTG(Leu)^CTA(Leu) Silent 
H2 8 14513 282： ^ C G G ( A ^ ^ G e f f r ^ ^^^ Missense ： 
' 'z ‘ ~ “ . - .... '^, «. 1^  />:#*' ^li-,、- — 、 
H3 Intron 6 13250 ctgggg ^ctgagg Missense 
H4 ^ 5 ; 1 ^ 3 " ， 4 f ^ J l ^ C f C ^ ^ f y ^ ; : ^ 、 ( : : ' I ^ ^ ^ $ 
'•?' ^ .'"'氣C^f*^^J�'�’ ^ \ ^^.^Ai \L-�•<, ； .«^. >,4^  .x^*l^c>* ：•'•! „ -- #5¾;; -"% 
H5 6 13337 193 CAT(His)<>TAT(Tyr) Missense 
H6 6 13416 219 CCC(Pro)^CTC(Leu) Misse&e, : f 
Intron 7 14448 gagtagTGGH>gaatagTGG Splicing> } 
8 14493 275 TGT(Cys)<>TAT(Tyr) . Missense '：' 
H7 7 14005 226 GGC(Glu)<>bGG(Glu) Silent 一 
H l l Intron 7 13450 ggggtc ^ ggcgtc Splicing 
H12 8 14469 267 CGG(Arg)OCAG(Gln) Missense 
L2 5 13057 126 TAC(Tyr)^TGC(Cys) Missense 
5 13085 136 CAA(Gln)^TAA(Stop) Nonsense 
Intron 6 13983 gcctgt <> gtctgt Splicing 
L3 8 14464 265 CTG(Leu)OCTA(LQu) Silent 
8 14570 301 CCA(Pro)<>TCA(Ser) Missense 
L4 6 13411 217 GTGCV^al)«^>GTA(Val) Silent 
7 14089 254 ATCaie)<>ATI(Ile) Silent 
L5 Intron 7 13450 ggggtc <> ggcgtc Splicing 
8 14537 290 CGC(Arg)<^TGC(Cys) Missense 
L7 6 13404 215 AGT(Ser)^AAT(Asn) Missense 
L8 8 14580 304 ACT(Thr)^'ArT(IIa) Missense 
7 7 
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Figure LL 
Gastritis with Helicobacter Pylori (HP) infection showing MALT-like features: 
(A) Low power of gastritis shows lamina propria expanded by the 
lymphoplasmacytic cells (indicated by arrow). (H&E X100) 
(B) High power of gastritis shows HP (indicated by 今),subepithelial plasma cells 
(indicated by + ) and intraepithelial lymphocytes (indicated by ).(H&E X200) 
/ A v^^v^ V; : ’�� ‘ *v t W ; B f e ^ 々 ： V • •«•# ^ ‘：• 二'; 
观、、祐'|‘、，C - : 5 — ” 鄉 》 ; A � - " > \ • 
、.,二 ” � ‘ H , t 、 : : , / ; 、 、 ： 々 卞 办 乂 ： " 广 \ ; 
^•r： i ' ; ^ ; : ? , . : : : . ^ . : : ^ > ^ / . 。 ， % ^\J^',4^：. A 
, 他 _ : . : 多 ， , 、 《 ” ‘：1 � 4 二 ^ ^ ， t ‘ 
^ ¾ ¾ : ^ " - ¾ : ^ 、 ? 〜 込 1 沾 ， , 、 ： ^ ^ 、 ‘ 
.'» ., - ‘ jp/ :"^ T^ ,.<ff.<fc*..<;#i^ vr...f9."*^ -' >.� t i ^ *j 4^ 4.. • • ' ' ^ * ' r 1» ^ ^  '；••»'^ *^ „0 m 
-^.,:;:》，;>，.,9，”,：;:厂,f&^:^t'&%\ V；> % ” 
. . 7 ? ; ? ‘ v ； 鼻 4 % - r r ^ . . ^ ; ' ; ' . 0 & A F - '^j%《〜::•、^ ‘ ， _ 
•3^ ^y； *^^ ‘ :-Y<. — -^' -/U*”4 ^ L A ^ > . X • **^‘^ - I 
- , X «% *•’ • /'. • “ -^-^ «- ^ ^‘^ ' i' ? I L^*^ T * • i T ^ 'm ’ *M • ‘‘ 
,* ^A/-r ' .^ *'i- ^ « 傲 • • •'' V 冬‘^A^t#-^ , VT'I* %^' 'mTM • ^ # .,.•• ^ ^^"v <j4i (.。巧.® •'； •'.;^,-^-".' - %\• v«r-fe*>f 1¾ • .'• ^  . % ：‘ 
^ ' ^ ' j v . -^  *'^ ¾. ^^ . ,» 丄’.,.®,、,= ' Ht**Z^^t V ' * ^ A^  X^-^I^ **^ .!.场类广 
; > v ^ > ^ . % - f , o . ^ ^ : y v j . y : g " * : v i k j ^ 5 V ^ ^ k ^ - h * 
M - ' S . ^ ¾ ¾ : , : ( D ) j j ^ \ 
/ ;.；•： . ' . . . . V 、 . ">:、•;々,， | S Q L 
;:':•::: '1:5.^^--;:¾-:.’,•:,:/��.« wn^ 
.::•:-、'•.“、.。'•：-、：，. 、、'、••)• >.-’，-~ l f l H T ^ 9 9 f i ^ 
.•‘'":. ：？、？>、：： >'； , .v , -. ^ 3 k l P I ^ 
:，::•,:.:. 乂/广.:,:,,： I - ^ K i ^ ^ 
. �扬 \ J ^ ^ K ^ 
•':%•,: . , S^KS^  
'..""/、;:,-•‘•；、、、<-<;••.•‘ W S A \ 
• : :。 - ^ ' ' ^ . v ^ > ^ ' - '：：^-.：••..；" y lm^ hl ‘ 
‘• , •.、 ^^ ^^p|B|p^B|a^ B^' 
^ v - . " • . . \ . ^^ '*."..^^  /' 、.’-、）•":‘、•'-、 、“ • W^^^Pr 
;•-''‘、、•‘.、/-‘"- — ,,,””” ：.-. . 、 *- f Q t F ,..•'‘ ‘ .>'... - - 乂 .广，、 ‘ W^ J .”• . • , .、.、.<，’，.：.f : ' 、 " ^ , / . *i *.：, -^ ' ‘： * ^ ' . . u ' / ¾ ' . ^ » ' , ’ , - " , '^^^ . 
?"•、：- ''.； ^>vzCr^”-::*r'〜:’“.：” , 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ j ^ ^ ^ * ^ ^ ^ ^ ^ ^ ^ . ： . -
Figure L2. 
Characteristics of low grade MALT lymphoma shows: (A) centrocyte-like 
cells (H&E, X200), (B) lymphoepithelial lesions (marked by arrows) (H&E, 
X200); (C) plasmacytic differentiation (H&E, X100), (D) lymphoepithelial 
lesions (immunostain for cytokeratin, X200) 
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Figure L3. 
High grade MALT lymphoma shows: 
(A) transition of low and high grade areas (H&E X200) 
(B) lymphoepithelial lesion. (H&E; X400) 
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Figure L4, 
Case o fDLCL shows: 
(A) diffuse sheet oflarge cells (H&E X200) 
(B) positive dark-brown signals ofEBERs by in-situ hybridization. (X200) 
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Figure IV.1, 
Immunostaining for p53 MoAb in high grade MALT lymphoma 
(A) high grade and (B) low grade area. (X200) 
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FigureIV.2. 
Immunostaining for bcl-2 in 
(A) low grade M A L T lymphoma (X200) 
(B) High grade M A L T lymphoma: low grade area and(C) high grade area (X200) 
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FigureB^.3 
Immunostaining for bcl-2 MoAb in benign gastritis. Positively stained plasma cells and 
lymphocytes (A) low power (X100) and (B) high power (X200). 
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Figure lV,4. 
Benign gastric mucosa shows follicle: (A) A cuff o f T cells stained by UCHL-
1 (T cell marker) (X100); (B) immunostaining for bcl-2, T cells and some 
mantle cells are positively stained. (X100) 
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Figure !V.5. 
Diffuse large cell lymphoma: 
(A) Immunostaining for bcl-2 is negative (X200) 
(B) Immunostaining for p53 is strongly positive (X200) 
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FigureIV.6. 
Direct D N A sequencing analysis o f p53 in H M , case H6. Sequence analysis reveals 
2 missense and lspl ic ing mutations at different positions. I t shows a missense 
mutation wi th base substitution o f CCC to CTC at codon 219, one splicing mutation 
wi th base substitution o f gagtag to gaatag at position 14448 and one missense 
mutation wi th base substitution o f T G T to T A T at codon 275. Note that mutations in 
both exon 6 and intron 7are absent in DLCL . 
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FigureIVJ. 
Representative result of mutational analysis of p53 in DLCL, case DL8. (A) 
PCR-SSCP analysis on exon 7 of p53 which shows the mobility shift (indicated 
by the arrow) in DL8. (B) Direct DNA sequencing analysis of exon 7 reveals a 
missense mutation with base substitution of GGC to AGC at codon 245, 
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FigureIV.8. 
Representative result o f mutational analysis o f p53 in DLCL , case DL2. (A) 
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FigureIV.10. 
Results o f L O H analysis o fDLCL , case DL4. N，normal; T, Tumor; L，loss of 
heterozygosity and ESf，mircosatellite instability (indicated by arrows). 
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FigureIVJL 
Representative results of LOH analysis at loci on chromosome 17pl2-13.1 
in different lymphomas. N，normal; T, tumor; arrowhead indicates 
microsatellite instability and arrows indicate allelic loss. 
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Results of LOH analysis showing both microsatellite instability 
(rN) and loss of heterozygosity (L) in DLCL. Note that these two 
cases with LOH abnormalities are negative for p53 mutations by 
screening with PCR-SSCP. 
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